Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
 Phase 2b Study of the Safety, Immunogenicity , and Efficacy  
of a monovalent synthetic carbohydrate -based conjugate 
vaccine (SF2a -TT15 ) for protection against  Shigella flexneri  
2a experimental infection  
 
 
Protocol Number:  Shigella CVD 30000  
 
 
Sponsored by:  
Karen L. Kotloff, MD  
 
Vaccine Developer : 
Institut Pasteur (Paris, France)  
 
Funding by: 
Institut Pasteur  (Paris, France ) 
 
Principal Investigator :  
Wilbur H. Chen, MD, MS  
 
Clinical Site:  
Center for Vaccine Development  & Global Health  
University of Maryland School of Medicine  
Baltimore, MD 21201  
U.S.A. 
 
Version Number: 14.0 
04 October  2023 
 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
i Statement of Compliance  
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by the 
following:  
• U.S. Code of Federal Regulations applicable to clinical studies (45 CFR Part 46, 21 CFR Part 
50, 21 CFR Part 54, 21 CFR Part 56, and 21 CFR Part 312 ) 
• International Conference on Harmonization (I CH) E6; 62 Federal Register 25691 ( 1997  and 
future revisions)  
• The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule -Final 
Modification (45 CFR Parts 160 and 164)  
• The local laws and regulations, which  prevail over the Un iversity of Maryland, Baltimore  
• Any terms of the award from the Bill & Melinda Gates Foundation  
Compliance with these standards provides public assurance that the rights, safety, and well -being 
of study participants are protected, consistent with the principles that have their origin in the 
Declarati on of Helsinki.  
All key personnel (all individuals responsible for the conduct of this trial) have completed Human 
Subjects Protection Training.  
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 
 ________________________________ ________________________________ ____________________________   
ii SIGNATURE PAGE  
The signature below constitutes the approval of this protocol and the attachments, and provides  
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations an d ICH guidelines.  
 
Site Investigator:  
 
Signed:   Date:   
 Name  
Title 
   
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
Table of Contents  
 page  
 ________________________________ ________________________________ ____________________________   
iii Statement of Compliance  ................................ ................................ ................................ .............  i 
Signature Page  ................................ ................................ ................................ ...........................  ii 
List of Abbreviations  ................................ ................................ ................................ ....................  v 
Protocol Summary  ................................ ................................ ................................ .....................  vi 
 
1 Key Roles  ................................ ................................ ................................ .........................  11 
2 Background Information and Scientific Rationale ................................ ..............................  13 
2.1 Background Information  ................................ ................................ ........................  13 
2.1.1  Clinical Illness with Shigella  Infection  ................................ ........................  13 
2.1.2  Antibody Responses to Shigella  ................................ ................................  14 
2.1.3  Polysaccharide Conjugate -Based Vaccine Development  ..........................  14 
2.2 Rationale  ................................ ................................ ................................ ..............  17 
2.3 Potential Risks and Benefits  ................................ ................................ .................  18 
2.3.1  Potential Risks  ................................ ................................ ..........................  18 
2.3.2  Known Potential Benefits ................................ ................................ ...........  20 
3 Study Design  ................................ ................................ ................................ ....................  22 
4 Study Population  ................................ ................................ ................................ ..............  24 
4.1 Study Population  ................................ ................................ ................................ ... 24 
4.2 Inclusion/Exclusion Criteria  ................................ ................................ ...................  24 
4.3 Enrollment and Randomization Procedures  ................................ ..........................  26 
4.4 Withdrawal from Study  ................................ ................................ ..........................  27 
5 Study Products  ................................ ................................ ................................ .................  29 
5.1 Study Vaccine, SF2a -TT15  ................................ ................................ ...................  29 
5.1.1  Preparat ion of Vaccine Doses for Administration  ................................ ....... 29 
5.2 Placebo, Sterile Saline  ................................ ................................ ..........................  29 
5.2.1  Preparation of Placebo Doses for Administration  ................................ ...... 29 
5.3 Study Product Accountability  ................................ ................................ ................  30 
5.4 Masking of the Study Product  ................................ ................................ ...............  30 
5.5 Challenge Agent, S. flexneri  2a strain 2457T  ................................ ........................  30 
5.5.1  Preparation of Challenge Inoculum  ................................ ...........................  30 
5.5.2  Preparation of Bicarbonate Buffer  ................................ .............................  31 
5.5.3  Administration of Challenge Agent to Participants  ................................ ..... 31 
6 Study Procedures/Evaluations  ................................ ................................ ..........................  32 
6.1 Study Procedures  ................................ ................................ ................................ . 32 
6.2 Laboratory Evaluations  ................................ ................................ .........................  37 
6.2.1  Labora tory Evaluations/Assays  ................................ ................................ . 37 
6.2.2  Special Assays or Procedures  ................................ ................................ ... 37 
6.2.3  Specimen Collection, Preparation, Handling and Shipping  ........................  39 
7 Study Schedule  ................................ ................................ ................................ ................  40 
7.1 Screening ( -60 to -1 days prior to enrollment)  ................................ .......................  40 
7.2 Visit 1 - Enrollment and Vaccination Dose #1 (Day 1)  ................................ ...........  41 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
Table of Contents  
 page  
 ________________________________ ________________________________ ____________________________   
iv 7.3 Visit 2 – Clinic Follow -up Post -Dose #1 (Day 8, +1 day window)  ...........................  42 
7.4 Visit 3 – Vaccination Dose #2 (Day  29, ±2 day window)  ................................ ........  42 
7.5 Visit 4 – Clinic Follow -up Post -Dose #2 (7 days post -2nd vaccination, +1 day 
window)  ................................ ................................ ................................ ................  43 
7.6 Inpatient Containment Period (~Day 55 -66, or challenge timed t o be ~28 days 
post-2nd vaccination)  ................................ ................................ .............................  43 
7.6.1  Acclimatization (2 days prior to challenge)  ................................ ................  43 
7.6.2  Challenge  ................................ ................................ ................................ .. 44 
7.6.3  Post-Challenge Observation Period (until discharge)  ................................  45 
7.6.4  Criteria for Discharge  ................................ ................................ ................  45 
7.7 Visit 5 – Clinic Follow -Up, only for those not in Challenge phase (28 days post -2nd 
vaccination, ±3 days window)  ................................ ................................ ...............  46 
7.8 Visit 6 – Clinic Follow -up (~7 days from discharge, +7 day window, only for those in 
the Challenge phase)  ................................ ................................ ............................  46 
7.9 Visit 7 – Clinic Follow -Up (~56 days post -2nd vaccination, ±3 days window)  ........  46 
7.10  Visit 8 – Clinic Follow -Up (~16 weeks post -2nd vaccination, ±7 days window)  ....... 47 
7.11  Visit 9 – Last Follow -up (~6 months post -challenge or post -visit 5, ±14 days 
window)  ................................ ................................ ................................ ................  47 
7.12  Unscheduled Visit(s) or Early Termination Visits, if applicable  ..............................  47 
7.13  Special Consideration for COVID -19 ................................ ................................ ..... 48 
8 Safety assessment and reporting  ................................ ................................ .....................  49 
8.1 Definition of Adverse Event (AE)  ................................ ................................ ...........  49 
8.1.1  Grading of Severity of an AE  ................................ ................................ ..... 49 
8.1.2  Relationship to Study Product  ................................ ................................ ... 50 
8.2 Definition of Serious Adverse Event (SAE)  ................................ ...........................  50 
8.3 Reporting Procedures  ................................ ................................ ...........................  50 
8.3.1  Serious Adverse Event Detection and Reporting  ................................ ....... 51 
8.3.2  Reporting of Pregnancy  ................................ ................................ .............  51 
8.4 Halting Rules  ................................ ................................ ................................ ........  51 
8.5 Safety Oversight  ................................ ................................ ................................ ... 52 
9 Clinical Monitoring Structure  ................................ ................................ .............................  53 
9.1 Site Monitoring Plan  ................................ ................................ ..............................  53 
10 Statistical Considerations  ................................ ................................ ................................ . 54 
10.1  Sample Size Considerations  ................................ ................................ .................  54 
10.2  Statistical Analysis Plan  ................................ ................................ ........................  54 
10.3  General Statistical Principles  ................................ ................................ ................  56 
11 Quality Control and Quality Assurance  ................................ ................................ .............  58 
12 Ethics/Protecti on of Human Subjects  ................................ ................................ ................  59 
12.1  Ethical Standard  ................................ ................................ ................................ ... 59 
12.2  Institutional Review Board  ................................ ................................ ....................  59 
12.3  Informed Consent Process  ................................ ................................ ...................  59 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
Table of Contents  
 page  
 ________________________________ ________________________________ ____________________________   
v 12.4  Exclusion of Women, Minorities, and Children (Special Populations)  ....................  60 
12.5  Subject Compensation  ................................ ................................ ..........................  60 
12.6  Subject Confidentiality  ................................ ................................ ..........................  60 
12.7  Future Use of Stored Specimens  ................................ ................................ ..........  61 
13 Access to Source Data/Documents  ................................ ................................ ..................  62 
14 Data Handling and Record Keeping  ................................ ................................ .................  63 
15 Publication Policy  ................................ ................................ ................................ .............  65 
16 Literature References  ................................ ................................ ................................ ....... 67 
Appendix A1: Schedule of Events, challenge s ubjects (Cohorts 1 -3) ................................ ........  70 
Appendix A2: Schedule of Events, Vaccine -Only Subjects (Cohorts 1 -3) ................................ .. 71 
Appendix B: Screening Tests  ................................ ................................ ................................ .... 72 
Appendix C: Clinical Safety Lab Toxicity  ................................ ................................ ...................  73 
Appendix D: Endpoi nt Definitions for Shigellosis  ................................ ................................ ....... 74 
Appendix E: Criteria for the Early Initiation of Antibiotics  ................................ ...........................  75 
Appendix F: Sample Form for the Collection of Subjective Symptoms Which Contribute t o the 
Shigella Disease Severity Score  ................................ ................................ .......................  76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
List of Abbreviations  
 
 ________________________________ ________________________________ ____________________________   
vi AE Adverse Event  
ALT Alanine amino trans ferase  
ALS Antibody in Lymphocyte Supernatant  
ANC  Absolute Neutrophil Count  
ASC Antibody Secreting Cell  
CAPA  Corrective Action Preventative Action  
CFR Code of Federal Regulations  
cfu Colony Forming Units  
CHIM  Controlled Human Infection Model  
CIOMS  Council for International Organizations of Medical Sciences  
CRO  Contract Research Organization  
CTRIC  Clinical and Translational Research Informatics Center  
CVD  Center for Vaccine Development  & Global Health  
DCF Data Collection Form  
DSMB  Data and Safety Monitoring Board  
ECG  Electrocardiogram  
FDA Food and Drug Administration  
FWA  Federal -Wide Assurance  
GCP  Good Clinical Practice  
GEMS  Global Enteric Multicenter Study  
GMP  Good Manufacturing Practice  
GMT  Geometric Mean Titer 
Hg Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act  
HLA Human Leukocyte Antigen  
HRPO  Human Research Protections Office  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IDS Investigational Drug Service  
IEC Independent or Institutional Ethics Committee  
Ig Immunoglobulin  
IND Investigational New Drug  
IPA Invasion Plasmid Antigen  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
LPS Lipopolysaccharide  
MCB  Master Cell Bank  
MOP  Manual of Procedures  
MPO  Myeloperoxidase  
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
List of Abbreviations  
 
 ________________________________ ________________________________ ____________________________   
vii MSD  Moderate -to-Severe Diarrhea  
N Number (typically refers to subjects)  
NPP Notification of Privacy Practices  
NHP  Non-Human Primate  
O-Ag O-antigen  
OHRP  Office for Human Research Protections  
OPKA  Opsonphagocytic Killing Antibody  
ORS  Oral Rehydration Solution  
OS Oligosaccharide  
QA Quality Assurance  
QC Quality Control  
QM Quality Management  
QMP  Quality Management Plan  
PBMC  Peripheral Blood Mononuclear Cell  
PBS Phosphate Buffered Saline  
PI Principal Investigator  
PP Per Protocol  
RBC  Red Blood Cell  
RU Repeating unit  
SAE Serious Adverse Event  
SBA Serum Bactericidal Antibody  
SF2a  Shigella flexneri  2a 
SFC Spot forming cells  
SOP  Standard Operating Procedure  
TAU Tel Aviv University  
TT Tetanus toxoid  
UMB  University of Maryland, Baltimore  
UMMC  University of Maryland Medical Center  
UP Unanticipated Problem  
USP United States Pharmacopeia  
WBC  White Blood Cell  
WRAIR  Walter Reed Army Institute of Research  
WHO  World Health Organization  
 
 
 
 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
viii Title: Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a 
monovalent synthetic carbohydrate -based conjugate vaccine (SF2a -TT15) 
for protection against Shigella flexneri  2a experimental infection  
 
Population : Approximately  ninety  healthy adults  age 18 -45 years from the Baltimore -
Washington  metropolitan area  will be enrolled  
 
Number of Sites : single site  
 
Study Duration : 1.5 years  
 
Subject Duration : 8 months, not inclusive of the screening period of up to 60 days  
 
Study Products : Vaccine . SF2a -TT15  is a prototype  monovalent  Shigella  flexneri 2a 
vaccine, consist ing of a synthetic pentadecasaccharide hapten 
corresponding to three repeating units of the S. flexneri  2a O-antigen and 
conjugated to tetanus toxoid.  The product, ~ 1500 GMP vials, each 
containing 40 µg/mL  of oligosaccharide was manufactured by Intravacc 
(Bilthoven, The Netherlands) . The vaccine is to be diluted to th e proper 
dose with the provided Alhydrogel  adjuvant , and delivered intramusc ularly.  
 Placebo . Sterile saline solution  alone , delivered intramuscularly in blinded 
fashion . 
 
Challenge Agent . Wild -type, live S. flexneri  2a strain 2457 T is to be freshly 
harvested and diluted in sterile phosphate buffered  saline  to reach the 
desired inoculum.  
Objectives : 
Primary Objective :  
• To assess the efficacy of SF2a -TT15 vaccination against Moderate -Severe Shigellosis 
Illness ( Appendix D ), as elicited by challenge with wild -type S. flexneri  2a strain 2457T.  
Secondary Objectives : 
1. To measure  the safety and clinical tolerability of two sequential doses of SF2a -TT15  
2. To evaluate  the performance of efficacy of SF2a -TT15 vaccin ation against different case 
definitions and endpoint definitions ( Appendix D ), as elicited by challenge with wild -type 
S. flexneri  2a strain 2457T.  
3. To evaluate the efficacy of SF2a -TT15 vaccination against any positive (qualitative) or 
quantitative fecal shedding of wi ld-type S. flexneri  2a.  
4. To measure the serum IgG immune responses to SF2a LPS following vaccination and 
challenge.  
5. To measure the bactericidal activity of SF2a -specific IgG following vaccination and 
challenge.  
6. To measure the IgA and IgG antibody secreting cell s (ASC) and antibody in lymphocyte 
supernatant (ALS) immune responses to SF2a LPS following vaccination  and challenge . 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
ix Exploratory Objectives : 
1. To measure pro -inflammatory cytokine markers in stool s following challenge  
2. To measure IgG subclasse s (IgG1 and IgG2) to SF2a LPS following vaccination and 
challenge  
3. To measure serum IgA immune responses to SF2a LPS following vaccination and 
challenge  
4. To measure urinary secretory IgA to SF2a LPS following vaccination and challenge and 
to store urine samp les for potential later analysis of anti -SF2a LPS IgG  
5. To measure the IgA and IgG ASC expressing mucosal and other homing molecules  (e.g., 
integrin α4β7 -positive) to SF2a LPS following vaccination and challenge  
6. To explore the correlates of immunity with protection  
7. To compare the immunologic assays performed by different research laboratories  
8. To collect, separate and store (at -70° C or colder) peripheral blood mononuclear cells 
(PBMC) so that in future studies the immune responses to SF2a -TT15 can be further 
characterized in great detail, including the measurement of memory , effector and other 
T cell subsets , B memory cells  and other B cell subsets , expression of homing 
molecules, cytokine production  and innate immune responses.  
9. To collect and store serum, urine , and stool specimens for future studies , including but 
not limited to antibody microarray analysis, fecal 16S rRNA microbiome , transcriptomics, 
proteomics  and other “omics” . 
 
Brief Description of Study Design :  
This will be a phase 2b, double -blind, placebo -controlled, single -center study, involving a 
vaccination phase and a challenge phase. The vaccination phase will consist of study participants 
that will be 1:1 randomized to receive either the vaccine or placebo. Two doses of blinded study 
product will be given by intramuscular route of administrat ion, separated by approximately 4 
weeks. The challenge phase will consist of an inpatient stay of approximately 12 days during 
which eligible study participants will ingest an oral inoculum of wild -type S flexneri  2a strain 2457T 
and then be monitored for illness  and treated with antibiotics when the primary endpoint is reached 
or upon 5 days post -challenge, whichever comes first, or when deemed necessary . Upon 
satisfying discharge criteria, study participants will complete outpatient clinic follow -up visit s 
through ~7 months after last dose of blinded study product (Day 237).  The efficacy  study will be 
enrolled through three cohorts of participants, each cohort consisting of approximately 30 subjects 
that will be involved in the vaccination phase and 22 su bjects that will proceed with the challenge 
phase.  
 
Schematic of Study:  
 
Vaccination Phase  
Cohort  Setting  No. 
doses  Target 
Enrollment  No. Subjects anticipated with 
1:1 randomization  
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
x SF2a -TT15 Placebo  
1 Outpatient  2 30 15 15 
2 Outpatient  2 30 15 15 
3 Outpatient  2 30 15 15 
 
Challenge Phase  
Cohort  Setting  Target No. Challenge  No. Subjects expected to be 
challenged, by their  1:1 
randomization  
SF2a -TT15 Placebo  
1 Inpatient  22 11 11 
2 Inpatient  22 11 11 
3 Inpatient  22 11 11 
 
 
 
 
 
 
 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
11 1 KEY ROLES  
Individuals : Principal Investigator    
 Wilbur H. Chen, MD, MS  
Professor of Medicine  
Direct Office Phone: 410 -706-1188  
Mobile Phone: 443 -414-4462  
wchen@som.umaryland.edu  
CVD Immunology Collaborators  
Marcelo B. Sztein, MD  
Professor of Pediatrics, Medicine, and Microbiology & Immunology  
Direct Office Phone: 410 -706-2345  
Mobile Phone: 443 -538-1734  
msztein@som.umaryland.edu  
 
Marcela F. Pasetti, PhD  
Professor of Pediatrics and Microbiology & Immunology  
Direct Office Phone: 410-706-2341  
mpasetti@som.umaryland.edu  
 
CVD Microbiology Collaborator  
Sharon M. Tennant, PhD  
Associate Professor of Medicine  
Direct Office Phone: 410 -706-5336  
stennant@som.umaryland.edu  
 
Clinical Site : Center for Vaccine Development  & Global Health  
University of Maryland School of Medicine  
685 W. Baltimore Street, Suite 480  
Baltimore, MD 21201  
 
Inpatient Research Isolation ward  
Pharmaron, 5th floor 
800 W. Baltimore Street  
Baltimore, MD 21201  
 
TAU Immunology Co llaborator  
Dani Cohen, PhD, MPH  
Professor of Epidemiology and Preventive Medicine  
School of Publ ic Health, Faculty of Medicine  
Tel Aviv University  
Direct Office Phone: 972-3-6407081  
dancohen@tauex.tau.ac.il  
 
WRAIR Immunology Co llaborator  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
12 LTC (P) Robert Cybulski , PhD  
Director, Bacterial Diseases Branch  
Walter Reed Army Institute of Research  
Office Phone:  301 -319-9511  
robert.j.cybulski.mil@health.mil  
 
Institut Pasteur  
Christiane Gerke, PhD  
Head of Vaccine Programs  
Institut Pasteur  
Paris, France  
Office: +33 1 45 68 80 90  
Cell Phone : +33 7 87 60 48 87  
christiane.gerke@pasteur.fr   
 
Mohand Ait -Ahmed  
Project Manager  
Center for Translational Research - Clinical Core  
Institut Pasteur  
28 rue du Docteur Roux  
Paris, 75015, Franc e  
Phone : +33 1 44 38 93 02  
Fax : + 33 1 40 61 39 77  
Mohand.ait -ahmed@pasteur.fr  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
13 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  
2.1 Background Information  
Diarrheal disease is a significant cause of morbidity and mortality worldwide; it is the second 
leading cause of death in children under the age of 5,1 with approximately 212,000 deaths 
annually. In 2016 , the global burden of Shigella  was estimated to  be the cause of  63,713  deaths 
in children under five years of age , predominantly  in developing countries.2,3 The Global Enteric 
Multicenter Study (GEMS) which investigated the cause of moderate -to-severe diarrhea (MSD) 
in children under 5 years of age in 7 sites in Africa and Asia identified Shigella  among the top 4 
pathogens.1 GEMS follow -on studies using molecular diagnostic methods revealed an increased 
attributable burden due to Shigella  and confirmed that it was the number 1 pathogen associated  
with MSD in the two older age strata (12 -23 and 24 -59 month olds) and fourth most important 
pathogen in the youngest 0 -11 month old age group across all sites.4,5 Moreover, Shigella  was 
disproportionately associated with severe outcomes. In indust rialized countries shigellosis, mostly 
S. sonnei , persists both as sporadic cases,6 and as a problem in certain sub -populations such as 
children in daycare and other settings with suboptimal personal hygiene.7 Shigella  also causes 
significant disease in travelers, including military personnel, to endemic regions.8,9  
The global public health importance of Shigella  is further substantiated by additional factors.  The 
increasing resistance to multiple antibiotics of Shigella  isolates reduces therapeutic options.7,10 
The World Health Organization has named Shigella  a priority for vaccine development and 
implementation but , despite intense efforts , no licensed vaccine to prevent Shigella  diarrheal 
illness is widely available.  Shigella  is also classified as a category B agent of biodefense concern, 
making it a priorit y for development of therapeutics and vaccines.  
2.1.1  Clinical Illness with Shigella  Infection  
After an incubation period of 1 to 4 days (as long as 8 days with S. dysenteriae  11,12), there is fever 
and constitutional symptoms such as headache, malaise, anorexia, and occasional vomiting. 
Watery diarrhea typically precedes dysentery11 and is often the sole clinical manifestation of mild 
infection.13 Progression to frank dysentery may occur within hours to days with frequent small 
stools containing blood and mucus, ac companied by lower abdominal cramps and rectal 
tenesmus. Most episodes of shigellosis in otherwise healthy individuals spontaneously resolve 
within 5 to 7 days without sequelae. Antibiotic treatment hastens clinical and microbiological cure. 
With repeated infections by the same serotype, illness is absent or attenuated and excretion is 
diminished.14-17 
A variety of extra -intestinal mani festations may occur. The most common is seizures, usually in 
febrile children without associated encephalopathy.18 A rare complication of S. dysenteriae  type 
1 infection is hemolytic uremic syndrome.19 Shigella  sepsis is uncommon and is usually seen in 
hosts with malnutrition or immunodeficiency. Occasionally , Shigella  causes focal extra -intestinal 
infecti ons like meningitis,20 arthritis,21 splenic abscess,22 and osteomyelitis ,23 in children . 
Persistent diarrhea and malnutrition are the most common chronic sequelae,24 seen in children 
from developing countries. A rare post -infectious complication that occurs mostly in adults is a 
reactive inflammatory ar thritis, alone25 or as part of a constellation of arthritis, conjunctivitis or 
iritis, and urethritis.26 This r eactive arthritis is a spondyloarthropathic disorder characte rized by 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
14 inflammation of the joints and tissues occurring after gastrointestinal or genitourinary infections , 
including : Campylobacter , Salmonella , and Shigella . Arthritis begins 2 to 4 weeks after the 
intestinal illness  and the j oint symptoms range from m ild arthralgia to severe polyarthritis and may 
become chronic in about 10% of cases. Individuals with the human leukocyte antigen (HLA) -B27 
histocompatibility antigen are predisposed, accounting for a t least one-half of the cases.27 The 
risk to the remaining 92 -99% of the population that is HLA -B27 negative is extremely low.28 
2.1.2  Antibody Responses to Shigella  
Naturally -acquired wild -type Shigella  infection confers serotype -specific immunity.13,16,29 
Moreover, adult subjects experimentally infected with either S. sonnei  or S. flexneri  are 
significantly protected against illness following re -challenge with the homologous strain (64 -74% 
efficac y).14,15 The specific immune responses that mediate protection against s higellosis have not 
been clearly elucidated. Several lines of evidence suggest an important role for anti -LPS 
antibodies. Israeli soldiers who lacked or had low titers of anti -LPS antibody were significantly 
more likely than seropositives to develop illnes s following exposure to the homologous S. sonnei  
or S. flexneri  strain during military camp outbreaks.29 Similarly, subjects who received bivalent 
Salmonella Typhi  Ty21a -S. sonnei  vaccine but lacked anti -LPS antibody were 3 to 7 times more 
likely to develop shigellosis following wild type S. sonnei  challenge compared with seropositive 
vaccine recipients.30 
Immune responses to Shigella  plasmid -encoded outer membrane proteins  (invasion plasmid 
antigens) IpaA, B, C and D and VirG are also encountered.31 In contrast to the O antigen, these 
peptides are shared among the four serog roups; however, their role in conferring protective 
immunity remains uncertain.  
2.1.3  Polysaccharide Conjugate -Based Vaccine Development  
A multitude of strategies ha ve been pursued to develop vaccines against Shigella  including live 
attenuated, killed whole cel l, subunit , and conjugate  vaccine s.32-34 Protective immunity against 
Shigella  is directed against the LPS O -antigen (O-Ag) and is serogroup -specific and often 
serotype -specific.35 Upon natural infection, experimental infection, or following vaccination, the  
antibody -mediated protection has been shown to be serotype specific, pointing to the O-Ag as 
the major protective antigen.  
S. flexneri  serotypes are defined by the structure of the oligosaccharide (OS) repeating unit (RU) 
that forms the O -Ag. For the pre dominant S. flexneri  serotype 2a (SF2a), the biological RU is a 
branched pentasaccharide.   Traditional g lycoconjugate vaccines candidates  are based on the use 
of detoxified LPS  and present some drawbacks such as the need for accurate control of the LPS 
purification and detoxification steps and of the conjugation procedure to avoid impurities  of 
biological origin and potential loss of immunogenicity upon chemical manipulation, including 
random conjugation to the protein carrier. An alternative strategy for t he creation of a 
glycoconjugate vaccine is based on the use of chemically defined synthetic OSs identified as 
functional mimics of the natural O -Ag, which are covalently linked via single point attachm ent onto 
an appropriate carrier protein . 
Rationally designed synthetic OSs of different lengths (di - to 20 -mers) were chemically 
synthesized and covalently linked via single point attachment to a carrier  protein , tetanus toxoid 
(TT). Upon testing their immunogenicity in vivo, the 15mer  glycoconju gate vaccine candidate 
(Figure below ) was identified as the optimal  antigenic, conformational and structural mimic of the 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
15 SF2a O -Ag. This 15mer glycoconjugate was also capable of eliciting a serotype -specific 
protective Ab response. The 15mer OS was also used in the form of a liposome -based diepitope 
immunogen and was observed to be  a promising functional mimic of the SF2a O -Ag.  Taken 
together, these data supported the advancement of the clinical development of the SF2a  15mer 
OS covalently linked to TT, al so termed SF2a -TT15.  
 
A pre -clinical GMP lot of SF2a -TT15 was evaluated for immunogenicity in BALB/c mice.  Mice 
were immunized with SF2a -TT15 alone or with Alhydrogel  adjuvant  (aluminum hydroxide, 
Brenntag, Denmark) .  Three sequential intramuscular doses of 0.5 µg, 2.5 µg, or 10 µg by OS 
weight was administered every 3 weeks, and a fourth booster dose was administered 1 month 
followed the third dose.  The serum anti -SF2a LPS  IgG ELISA titers were measured after the third 
and fourth doses of vaccine.  As shown in the Figure below , whatever the dose tested, there was 
a significant increase of the IgG titer when administered with Alhydrogel . The 0.5 µg and 2.5 µg 
dose, but not the 10 µg dose , in the presence of Alhydrogel  also gave rise to significant increase s 
in the IgG titer when comparing the 3 and 4 sequential dose immunization  series . Together, these 
results indicate that it is possible to decrease the dose of the vaccine candi date to be used when 
adjuvanted with Alhydrogel .. These findings also justif ied the use of Alhydrogel  and of 2 different 
doses of our vaccine candidate in the Phase 1 clinical trial . 
 
 S3 S4
S3 + alum
S4 + alum02000400060008000100001200014000
*
**
***0,5ug 
**Anti-SF2a LPS IgG titer
 S3S4
S3 + alum
S4 + alum02000400060008000100001200014000
**
**
*2,5ug 
** S3 S4
S3+ alum
S4  + alum 02000400060008000100001200014000
**
***10ug 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
16 A GLP animal toxicity study with the pre -GMP SF2a -TT15 alone or adjuvanted with Alhydrogel 
was conducted .  A total of 48 male and female New Zealand White albino rabbits  were immunized 
with four intramuscular doses of 10 µg SF2a -TT15 alone, 10 µg SF2a -TT15 with Alhydrogel, or 
placebo (saline) at 3 we ek intervals .  The scheduled blood sampling for clinical laboratory analysis 
and necropsy examinations did not demonstrate abnormalities —so the vaccine with or without 
adjuvant was considered well -tolerated in rabbits .  Serum anti -S. flexneri  2a LPS IgG EL ISA 
antibodies were measured . A significant increase in these specific antibodies was observed 
among animals that received SF2a -TT15 with Alhydrogel adjuvant and a plateau was achieved 
after 2 doses.  
 
A first-in-human, phase 1 clinical trial was performed  in Israel, at the Tel Aviv Sourasky Medical 
Center and Tel Aviv University with a GMP formulation of SF2a -TT15. Sixty four eligible 
participants were screened for low pre -existing S. flexneri  2a LPS antibody levels and HLA -B27 
seronegativity  and randomize d to receive vaccine alone, vaccine with Alhydrogel  adjuvant, or 
placebo. The vaccine was evaluated at 2 µg and 10 µg doses. Three sequential injections of the 
blinded study product w ere administered by intramuscular route at 1 month intervals and follow -
up was through 3 months after the last dose of vaccine.  The SF2a -TT15 vaccine, with or without 
Alhydrogel , was well -tolerated at both the dosage levels (2 µg and 10 µg doses).  With 2 µg  doses, 
the first vaccine dose induced significant rises in serum anti -S. flexneri  2a LPS IgG, with geometric 
mean titers (GMT) of ~5 -fold over baseline or compared to placebo recipients. Alhydrogel  
adjuvanted doses enhanced these serum antibody responses after the second and third dose of 
vaccine with ~8.5 and ~12 -fold increases in GMT.  The first dose of the 10 µg dose vaccine elicited 
GMT fold increases over baseline of ~25 -fold and ~27 -fold when administered with or without 
Alhydrogel ; there was no furt her detectable increase subsequent to the second and third dose of 
vaccine (adjuvanted or non -adjuvanted).  However, the peak level of the antibody response was 
maintained longer if the vaccine was administered with Alhydrogel. All vaccinees receiving the 10 
µg dose (with or without Alhydrogel) were responders after the first dose of vaccine (responses 
defined as 4 -fold or greater increases in antibody titer over baseline). Furthermore, vaccination 
induced ~15 -fold increases in serum bactericidal antibody ( range of post -vaccination GMT 5918 -
14669); there was an 88% response rate (4 -fold or greater increase) in serum bactericidal titer 
after the first dose of vaccine. In conclusion, these results support the further clinical development 
of the SF2a -TT15 vacci ne candidate at the 10 µg dose, delivered with Alhydrogel  adjuvant, in a 

Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
17 one or two-dose regimen.36   
2.2 Rationale  
Since 1992, 3973 volunteers (974 adults and 2999 children aged 1 -7 years ) have received first 
generation Shigella  conjugate vaccine candidates, including S. dysente riae 1, S. sonnei  and S. 
flexneri 2a  conjugate vaccines manufactured at the National Institutes of Health using traditional 
chemical O -PS extraction  and conjugation techniques .  
These investigational Shigella  conjugate  vaccine s showed a very good safety profile similar to 
the other conjugates licensed and widely used in national immunization programs all over the 
world. The serum immune response was stronger and longer lasting than that induced by natural 
infection. The S. sonn ei conjugate showed 74% protective efficacy in young adults37 and 71% 
protective efficacy in children aged 3 -4 years  but was not protective in younger children.38 The 
levels of serum IgG anti -LPS antibodies to S. sonnei  induced  by the conjugate vaccine correlated 
with protection against natural in fection. Improved conjugates are needed to be more 
immunogenic and confer protection in children less than 3 years of age.  
The SF2a -TT15 glycoconjugate vaccine candidate represents the next -generation of  
glucoconjugate  Shigella  vaccine . It has been developed by Institut Pasteur  (Paris, France), a 
French non -profit foundation which has a long -standing history of developing vaccines .  The 
safety and immunogenicity of SF2a -TT15 in a phase 1 trial in Israel  described above and  support s 
continue d clinical development .   
The intent of the planned study is to evaluate the efficacy  of SF2a -TT15  using a controlled human 
infection model (CHIM). Shigella  is a human -specific pathogen and no predictive animal model 
resembling human disease is available. While immunogenicity is assessed in animal models, 
efficacy testing in animals against intestinal disease similar to what occurs in humans is not 
feasible. Non-human primates (NHP) in captivity can be infected following very high doses, but 
these unintenti onal exposures limit the validity of this model for humans . In humans, the infectious 
dose can be as low as 10 bacteria. In NHP, a dose of 1010 bacteria is required to cause disease . 
Thus, the pre-clinical animal models which are available are so different  from human infection, 
making meaningful efficacy testing with these models im possible. Therefore, a controlled human 
infection model (CHIM) has been in use for more than 50 years  to obtain early efficacy read -outs 
for Shigella  vaccine candidates as an important decision point for further development and  to 
identify the most promising candidates for further development.  Only if protection is observed 
following vaccination  and the CHIM will the SF2a -TT15 candidate be further developed into a 
multivalent Shigella  vaccine and undergo clinical testing to Phase III efficacy trials. The absence 
of demonstrable  protection in the CHIM would prevent  performing  large efficacy trials in young 
children and infants with a vaccine with little chances of success.  
The wild -type S. flexneri  2a strain 2457T challenge model has been in use for many decades , ans 
was first developed at the University of Maryland School of Medicine .11  A modern challenge 
model with 2457T has been in use since the early 1990s15 and is a nticipated  to elicit 80 -90% 
attack rates of illness according to the case definition employed among naïve study subjects that 
ingest ~1500 cfu organisms.  
To harmonize CHIM studies for Shigella  and thus allow for indirect comparisons of various 
Shigella  vaccine candidates, the Bill & Melinda Gates Foundation  (BMGF) organized a working 
group to define efficacy endpoints and immunological assays for guiding the scientific community 
(personal communication  with C. MacLennan, BMGF ). These modified efficacy endpoints reflect 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
18 moderate and severe shigellosis. Protec tion against these forms of shigellosis is currently 
deemed the most desirable feature of a successful vaccine. A post -hoc analysis of published 
studies was performed to determine the attack rate for these endpoints and an attack rate of 60% 
was estimated (Chad Porter, VASE 2018).  
Assuming an attack rate of 60%  among placebo controls , 33 subjects per group (vaccinees and 
controls) are required at 80% power to demonstrate 50% efficacy , with the lower limit of the 90% 
confidence interval larger than zero. Thus, 66 subjects will be randomized to receive vaccine or 
placebo and enrolled in the CHIM to evaluate the efficacy of SF2a -TT15. Based on local clinical 
site facilit y and staff  resources , the 66 subjects will be split into 3 cohorts of 22 subjects  each . To 
account for potential drop outs  between the vaccination and CHIM phase and to plan for back -
ups, up to 30 volunteers per cohort will be enrolled in the vaccination phase, thus a total of 90 
subjects  are targeted for enrollment . The exc ess of 8 subjects per cohort is based on experience 
of the Center for Vaccine Development ( CVD ) with previous human challenge studies.  
2.3 Potential Risks and Benefits  
This clinical trial will involve the use of non -licensed vaccines and human experimental inf ections 
(challenges) with a wild -type Shigella  organism. Therefore the design and implementation of this 
trial has been planned with the intent to minimize risk , pain, and discomfort , whenever possible. 
The sample size of the study has been calculated to expose as few persons as possible to the 
challenges (the  part of the study which carries the most potential risk). The challenges will be 
conducted under containment and the discharge of participants will only be done when they have 
demonstrated they no lon ger shed the organism, so that the risk for the pathogen to cause 
infections  in community contacts beyond the inpatient ward has been minimized.  Objective 
management of fluid losses and illness related to shigellosis are carefully described in the protocol 
(Section 5.6) and Manual of Procedures (MOP).  Early treatment with antibiotics will be initiated  
as necessary to lessen the duration and severity of shigellosis.  
2.3.1  Potential Risks  
Anticipated Reactions with an Injectable Conjugate Vaccine . Local injection site pain, swelling, 
tenderness, and warmth is anticipated, but is expected to be mild, of short d uration, and will self -
resolve.  Parenteral vaccines occasionally can also cause constitutional symptoms such as fever, 
aches, malaise, or anorexia.  As part of the objective to continue to measure the safety and 
potential reactogenicity of the vaccine, th e study will measure the local and systemic 
reactogenicity and will document unsolicited adverse events (AEs) which may be related to 
vaccination. Additional potential h ypersensitivity reactions to the vaccine are expected to be rare 
and unpredictable. Persons who have a history of anaphylaxis with tetanus containing vaccines 
will be excluded from participation.  
Shigellosis and Diarrheal Disease . The Shigella  challenge is intended to elicit sym ptoms 
consistent with shigellosis , including fever, headache, diarrhea, dysentery, abdominal cramps, 
tenesmus, nausea, and vomiting.  If a subject were to develop unacceptable symptoms  as 
described above  he/she will be offered early antibiotic therapy. Antipyretics and non -steroidal anti -
inflammatory  pain medications can be provided to alleviate some of the discomfort associated 
with shigellosis.  The potential exists for S. flexneri  strains to cause a dehydrating diarrheal 
disease.  Under the controlled management  in this study, the dehydrating effec ts of heavy purging 
can be prevented by giving oral rehydration solutions preventively after each loose stool (grade 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
19 3-5) and by early recognition of dehydration and prompt therapy with oral and intravenous fluids. 
If intravenous fluids are required, blood  chemistries will be monitored.  As a precaution, subjects 
who do not have prominent arm veins will be excluded from participating in the trial because this 
may pose difficulty in attaining venous access.  
Reactive Arthritis . A rare post -infectious complica tion that occurs mostly in adults who have had 
an infection with a wild type S. flexneri  serotype is reactive inflammatory arthritis, alone25 or as 
part of a constellation of arthritis, conjunctivitis or iritis (uveitis), and urethritis .26  Arthritis begins 
acutely usually 2 to 4 weeks after the intestinal illness.  Joint symptoms range from mil d arthralgia 
to severe polyarthritis and become chronic in about 10% of cases.  Persons with the HLA -B27 
histocompatibility antigen are predisposed, accounting for ~half of the cases .27 The risk to the 
remaining 92 -99% of the population that is HLA -B27 negative is thus extremely low.  Subjects 
who carry HLA -B27 will be excluded from participating in the study because of the remote 
possibility of inducing this arthri tis syndrome.  Uveitis can be a component of the syndrome (which 
has many causes), but to our knowledge has never been associated with Shigella infection. 
Uveitis in association with reactive inflammatory arthritis can cause pain, eye redness, and visual 
disturbance.  Complete recovery within 3 months is the usual outcome.  
Bacteremia and/or Localized Infection . Even during infection with virulent Shigella  spp., available 
information suggests that bacteremia and localized infection are rare in persons of goo d nutritional 
state  and among adults .  Therefore, this theoretic risk is not specifically discussed in the consent 
form.  
Transmission and Secondary Spread of the Live Organism . The transmission of this organism is 
through the fecal -oral route.  Subjects wi ll be repeatedly educated during the course of the study 
about precautions (e.g., hygiene and toilet cleaning procedures) needed to prevent spread of the 
organism to close contacts.  Hand washing will be emphasized to the subjects.  Stools will be 
treated with bleach for five minutes prior to flushing.  Previous inpatient studies with wild type S. 
flexneri  2a at the CVD have not detected transmission  events . To prev ent the transmission of the 
organism outside of the research isolation ward, subjects must complete antibiotic therapy and 
lack the shedding of organisms in stools cultures prior to discharge.  
Hypersensitivity and/or Side Effects to Antibiotics . Subjects with known hypersensitivity to 
ciprofloxacin or trimethoprim -sulfamethoxazole will be excluded  from the study .  These licensed 
antibiotics have been widely used and have an excellent safety record; however, there remains a 
small risk that a hypersensitivit y reaction to the licensed antibiotic could occur, and in rare 
instances such reactions have been fatal.  The following reactions are seen rarely in persons 
taking ciprofloxacin: 1) gastrointestinal (GI) upset (e.g., upset stomach, nausea, vomiting, 
diarrh ea); 2) headache, dizziness, or light -headedness; 3) seizures (therefore subjects with a 
known seizure disorder may not participate); and 4) photosensitivity (so subjects are counseled 
to avoid such exposure); and 5) tendinitis (pain, inflammation, or rupt ured tendon).  Other 
reactions may occur from drug interactions, including caffeine, so subjects are not allowed to take 
any other medications which may interact with ciprofloxacin while they are participating in this 
trial, and are advised to avoid caffei nated beverages while taking ciprofloxacin. Uncommonly, 
reactions are seen with trimethoprim/sulfamethoxazole including:  GI upset, hypersensitivity, 
hepatitis, and blood dyscrasia.  These reactions are rare but can occasionally be fatal.  
Pregnancy . The vaccine  has not been evaluated in  pregnancy, so pregnant women may not 
participate in the study and women of child-bearing potential must agree to use effective methods 
of birth control for at least 4 week prior to enrollment and 4 weeks after last dose of  vaccination  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
20 or challenge .  Women  will be counseled  about the pregnancy precautions related to study 
participation .  
Blood Draws . Blood drawing may cause local pain, bruising, occasional lightheadedness, and 
rarely fainting.  Blood will be drawn by trained  personnel.  Subjects who are found to experience 
lightheadedness will lie down during and after they have their blood drawn.  The amount of blood 
drawn does not exceed that recommended by the American Red Cross.  
Confidentiality . Personal health information will be collected as a part of this study and efforts will 
be made to maintain confidentiality. There is a small risk of loss of confidentiality that an 
unauthorized person may gain access to viewing the research records. In order to maintain 
confidentiality, all study records will be stored in a secure location, such as a locked office and/or 
locked cabinet. Electronic data will be password -protected.  Study records and specimens 
obtained will be coded.  Research records will only be shared wit h authorized personnel and only 
in connection with carrying out the obligations relating to the study. Every effort will be made to 
keep the records as confidential as possible, within the limits of the law.  
Unexpected Risks . There may be other side effect s, including severe ones, which cannot be 
predicted.  
Special Circumstance  for COVID -19. As long as the threat of COVID -19 continues to represent a 
U.S. Public Health Emergency, a number of steps will be undertaken to protect research staff and 
study partic ipants from COVID -19. The eligibility criteria will include a question regarding the 
presence of symptomatic COVID -19-like illness, wherein a positive response of symptoms will 
exclude the participant from eligibility to be vaccinated. Also, all participan ts must have completed 
COVID -19 vaccination at least 14 days prior to challenge and each participant must test negative 
from a molecular diagnostic test prior to challenge. In order to separate the anticipated side effects 
of COVID -19 vaccination from the evaluation of the reactogenicity of the blinded study product, 
COVID -19 vaccines must not be administered within <14 days of scheduled blinded study product 
administration. These measures are intended to further reduce the risk of transmission of COVID -
19 on the inpatient setting from asymptomatic or pre -symptomatic participants.  
Furthermore, at all points during the conduct of the study, a number of non -pharmacologic 
interventions will be required.  The observance of universal masking, physical distancing, hand 
hygiene, administrative changes (e.g., decreasing the density of study personnel), and other 
control or mitigation measures will be implemented by research staff, as per the university 
policies.  All study participants will be required to wear a face mask and instructed to perform 
hand washing or hand sanitation during the inpatient period and for all scheduled outpatient visits.  
When the COVID -19 pandemic resolves and the U.S. Public Health Emergency has ended, the 
study team will re -evalu ate the local conditions for consideration of removing these additional 
precautionary measures.  
2.3.2  Known Potential Benefits  
This is a healthy volunteer study which does not provide any guarantee of benefit. The benefit is 
largely the scientific knowledge to be gained from the study , which will be an essential component 
of the development of a new vaccine, which may benefit many people and prevent illness and 
death in many developing countries .39,40  The development of Shigella  vaccines has long been 
impeded32,41,42 and there are no suitable a nimal models which can replace human studies.43 
There is the prospect that the study vaccine may confer protection aga inst S. flexneri  2a infection, 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
21 but the study is blinded and includes a control vaccine, thus this benefit is not guaranteed . There 
is no approved vaccine for Shigella  in the U.S.  
Participants will be provided access to the general results of the study, as these data are required 
to be made available through clinicaltrials.gov registry.  Participants may know, upon their 
request, their randomized vaccination group assignment; this will occur upon the closure of the 
study, locking of the data base, and unblinding of the study results.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
22 3 STUDY DESIGN  
This is a phase 2b, randomized, double -blind, placebo -controlled, single -center study  of the 
safety, immunogenicity, and preliminary efficacy of SF2a -TT15.  We hypothesize that the 
synthetic gly coconjugate Shigella  vaccine will demonstrate protection in a human volunteer 
challenge model using wild -type S. flexneri  2a strain 2457T. The study will consist of two phases, 
a vaccination phase and a challenge (CHIM) phase. The vaccination phase begins when 
volunteers who meet eligibility criteria following a screening process are  enrolled and  randomized 
to receive two doses of either vaccine or placebo  in a blinded fashion , with each dose separated 
by approximately 4 weeks .  Volunteers  complete an outpatient clinic follow -up visit approximately 
one week after each dose.   The target of the study is to vaccinate 90 volunteers of whom 66 will 
undergo CHIM;  approximately half (n=33) of the CHIM participants will have received 2 doses of 
the vaccine and the other half will have received 2 doses of placebo.  The logistical 
implementation of the study will be conducted with three cohorts of participants involved in the 
vaccination and subsequent challenge phases of the study.  
Eligible and available consenting volunteers in cohorts 1 -3 who have completed the vaccination 
phase will be eligible for the challenge phase, which includes an approximate 12 -day inpatient 
stay.  In order to ensure the target number of participants will complete  the challenge phase, for 
the primary objective of the assessment of efficacy, there is a plan to have additional volunteers 
available for participating in the challenge phase. For example, in order to meet a target of n=22 
challenged in a single cohort, t here will be  up to  30 participants enrolled into the vaccination phase 
of that cohort and there may be up to 26 eligible participants admitted to the inpatient ward during 
the acclimatization period (prior to challenge) . Thus 8 of these participants will s erve as “back -
ups” (8 of 30 persons per cohort that will not be challenged) , the identity of which participants are 
back -ups is blinded to the subject. An unblinded statistician will review the list of volunteers 
identified for challenge and for homing stu dies to ensure the proportion of vaccine and placebo 
recipients is balanced; when necessary, the unblinded statistician may recommend alternative 
study participants (among the back -ups) to ensure this balance.  Back-up participant s 
(participants on the inpatient ward during the acclimatization period who have not been 
challenged)  are immediately discharged  from the inpatient unit .   
The challenge phase is located in an inpatient setting (Research Isolation Ward) , during which 
time volunteers will be  inoculated with the wild -type Shigella  (S. flexneri  2a strain 2457T).  All 
participants will be monitored for the onset of illness and actively managed  to treat their 
symptoms . In order to be eligible for discharge, the participant must com plete a course of 
antibiotics, demonstrate no symptoms of illness, and provide two stool specimens which fail to 
grow S. flexneri  2a, the challenge organism.  
All participants, whether participating in the challenge or not, will continued to be followed thr ough 
approximately 7 months after the last dose of vaccine  for the collection of safety information . 
Plasmablast h oming studies (ASC and ASC homing  studies ) will be performed to identify the 
mucosal or systemic distribution of primed cells.  Because these studies are labor -intensive, they 
will be performed on a subset of up to 6 participants maximum per day  (or up to 8 
participants/cohort) —each cohort is intended to be vaccinated on 2 separate days . We anticipate 
that up to 24  volunteers in the vaccination phase and 18 volunteers in the challenge phase will 
participate in homing studies.  It is intended that the same participants in the homing studies for 
the vaccination phase be the same 18 participants in the homing studies during the challenge 
phase , therefore, in order to meet the number in the challenge phase, we plan to have more 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
23 participants (up to 24) in the homing studies for the vaccination phase . Participants in the homing 
studies will be selected somewhat randomly since  there will be an attempt to maintain both the 
blind and also the balance of vaccine and placebo recipients; priority for challenge will be given 
to homing study participants.  
 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
24 4 STUDY POPULATION  
4.1 Study Population  
Healthy subjects, ages 18 -45 years, will be recruited from the Baltimore -Washington area on the 
basis of general good health, expressed interest in the study as determined at a preliminary 
interview, satisfying all eligibility criteria, and availability for the challenge and required follow -up 
visits .  Approximately 90 subjects will be recruited and vaccinated, with the aim of challenging 66  
subjects.  Subjects must undergo medical screening and meet eligibility criteria within 60 days 
before vaccination . 
4.2 Inclusion/Exclusion Criteria  
Inclusion Criteria : 
1. Male or female of age 18 -45 years  
2. Provides written informed consent  
3. Healthy, based on history, exam, and medications  
4. Documented acceptable screening laboratory work, including:  
• WBC, ANC, Hg, Platelets  
• Creatinine, ALT, Bili  
• Serum IgA  
• HIV, HBsAg, HCV  
• Negative for HLA-B27  
• urinalysis  
5. Passing score on Comprehension Assessment Tool  (≥70% correct answers)  
6. Agrees not to participa te in another interventional clinical trial during the study period  
(approximately eight months)  
7. For females of child -bearing potential†, must agree to acceptable birth control *, 4 weeks 
before enrollment and through  4 weeks after last vaccination or challenge  
†  females of child -bearing potential are defined as: n ot sterilized via tubal ligation, bilateral 
oophorectomy, salpingectomy, hysterectomy, or successful Essure®  placement (permanent, 
non-surgical, non -hormonal sterilization) with documented radiological confirmation test at 
least  90 days after the procedure, and still menstruating or <1 year of the last menses if 
menopausal.  
*  acceptable birth control includes: n on-male sexual relationships, abstinence from sexual 
intercourse with a male partner, monogamous relationship with vasectomized partner who 
has been vasectomized for 180 days or more prior to the subject receiving the first study 
vaccination, barrier metho ds such as condoms or diaphragms with spermicide or foam, 
effective intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, 
injectables, or oral contraceptives.  
8. Available for a 12-day inpatient stay   
9. During the time when a U.S. Pub lic Health Emergency for COVID -19 exists, the 
participant must have completed an FDA EUA authorized COVID -19 vaccination , at 
least 14 days prior to challenge.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
25  
Exclusion Criteria : 
1. Positive pregnancy test at screening or within 24h of study product dosing  
2. Poor venous access, as defined by inability to obtain venous blood after 3 venipuncture 
attempts   
3. Abnormal vital signs, defined as:  
• Systolic BP>150 mmHg or Diastolic BP>90 mmHg  
• Resting heart rate >100  
• Oral temperature ≥ 100.4 °F 
4. Persons w ith IgA defic iency (serum IgA less than lower limit of reference range )  
5. Serum S. flexneri  2a LPS IgG titer of >2500  
6. Received prior vaccines or had prior infection  (natural or challenge)  with ETEC or 
Shigella , within 5 years prior to enrollment  
7. Received a COVID -19 vaccine within <14 day prior to enrollment (dose #1 of blinded 
study product) , within <14 days prior to dose #2 of blinded study product , or within <14 
days prior to challenge  
8. Symptoms of Traveler’s diarrhea associated with travel to co untries where Shigella  or 
other enteric infections are endemic (most of the developing world) within 3 years prior 
to enrollment  
9. History of chronic gastrointestinal illness, including severe dyspepsia, or other significant 
gastrointestinal tract disease  
10. Use of antibacterials within 2 weeks of each dose of vaccine or the challenge  
11. Regular use (≥weekly) of laxatives, anti -diarrheal agents, anti -constipation agents, or 
antacid therapies  
12. History of  major gastrointestinal surgery  (uncomplicated laparoscopic app endectomy or 
cholecystectomy >1 year prior is permitted)  
13. Abnormal bowel pattern , defined by <3 stools per week or >2 stools per day in the past 6 
months  
14. Use of oral, parenteral or high-dose inhaled steroids† within 30 days  of each dose of 
vaccine or the challenge  
†  high-dose oral steroids is defined as prednisone ≥ 20 mg total daily dose, or equivalent dose 
of other glucocorticoids; high -dose inhaled steroids is defined as >800 µg/day of 
beclomethasone dipropionate or equi valent  
15. Use of any medication which might affect immune function * within 30 days  of each dose 
of vaccine or the challenge  
*  examples include: anti -cancer chemotherapy, immunomodulatory medications for rheumatic 
diseases, and anti -rejection transplant medic ations  
16. Current medical condition which requires more than a single daily (2 or more)  prescribed 
medication for control (as medication use is limited during the inpatient stay) . In other 
words, a subject may be eligible if on a single medication for a stable, well -controlled 
medical condition which has not required any changes in dose or frequency over at least 
3 months. Any change in prescription due to a change in provider, insu rance, financial 
reasons, etc. and as long as the change in prescription remains in the same class of 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
26 medication will not be considered an ineligibility (is allowable towards the definition of a 
stable, well -controlled medical condition). Any change in pre scription medication due to 
an improvement of a condition will also not be considered an ineligibility. Under all 
circumstances, the medical condition which is being treated with the single medication 
must be reviewed and deemed to be acceptable by the jud gement of the investigator. 
The medical condition must not pose a significant risk to the participant nor to the safe 
conduct of the study.  
17. History of reactive arthritis  
18. Diagnosis of schizophrenia or other major psychiatric disease  
19. History of seizure disor der within the last 5 years  
20. History of a lcohol or drug abuse within last 5 years  
21. Presence of immunosuppression  
22. Known significant allergy  (i.e., anaphylaxis)  to ciprofloxacin , trimethoprim -
sulfamethoxazole  (Bactrim), or a tetanus -containing vaccine  
23. 12-lead electrocardiogram with pathologic abnormalities  (see Appendix B)   
24. Occupation in food handling industry , living with,  or care of very young children  (<5 years 
old), elderly  (>65 years) , or immunocompromise d  
25. Having any known legal obligations, court appearances, professional meetings, 
vacations, planned events, or other reasons which might interfere with a person’s 
availability for a 12 -day inpatient stay.   
26. During the time when a U.S. Public Health Emergenc y for COVID -19 exists, on the days 
of vaccination there is the presence of 2 or more of any of the following symptoms: fever 
(≥38°C), chills, myalgia, headache, sore throat, or new olfactory and/or taste disorder  
27. Any other criteria which, in the investigator’s opinion, would compromise the safety of 
the study, the ability of a subject to participate, or the results of the study  
4.3 Enrollment and Randomization Procedures  
Per International Conference on Harmonisation (ICH) guideline E6: Good Clinical Practice (GCP), 
screening records will be kept at the clinical site to document the reason why an individual was 
screened, but failed trial entry criteria. The reasons why individuals failed screening will be 
recorded in the data system.  
Based on local clinical site facility and staff resources,  subjects will be enrolled in 3 cohorts , each 
cohort consisting  of up to 30 subjects . Once consented and upon confirmation of eligibility for this 
trial, the subject will be enrolled and randomized. Subjects  will be randomized, within their 
respective cohort, in a 1:1 ratio to receive either vaccine or placebo.  The randomization code will 
be prepared by a statistician at the CVD . Within each cohort  (n=30) , randomization will be 
generated by computer to alloca te 15 participants to each group (vaccine or placebo)  using block 
randomization with varying block sizes 6, 8, 10 or 12 .  A designated individual at the site  will be 
provided with a code list for emergency unblinding purposes, which will be kept in a secur e place.  
Subjects who sign the informed consent form and are enrolled and randomized but do not receive 
study vaccine may be replaced. Subjects who sign the informed consent form, and are 
randomized and receive at least one dose of vaccine but subsequently  withdraw, or are 
withdrawn , or are terminated from this trial, or are lost to follow -up will not be replaced.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
27 Subjects that have completed 2 doses of blinded study product will be eligible for the challenge 
phase. Subjects that do not complete 2 doses of blinded study product and subjects who are 
determined to be ineligible or inappropriate for the challenge will not be replaced.  
4.4 Withdrawal from Study  
Reasons for Withdrawal or Termination . Participation in the study is strictly voluntary.  Participants 
have the right to withdraw from the study at any time and for any reason, without penalty  or 
prejudice to further treatment .  The Principal Investigator (PI) and/or designee may, at their own  
discretion, terminate  a subject from continuing in the study if it is considered to be in the 
participant’s best welfare , or if the participant is not willing or able to comply with the study 
requirements.  The reason for withdrawal or termination will be documented.  
There may  be participants that will be withdrawn from the challenge phase of the study, after 
successfully completing the vaccination phase. It is anticipated that some participants could be 
withdrawn due to inappropriate behavior or other unacceptable issues , which could present a risk 
to the participant, other subjects, the study staff, and/or jeopardize the conduct of the study.  
Participants may also withdraw from the study for any reason, even during the inpatient 
confinement .  These participants will be dischar ged from the inpatient unit (if present on the 
inpatient unit at the time of this determination)  and in the presence of a security guard, when 
applicable.   If the participant withdraws or is being removed after being challenged and prior to 
completion of a ll scheduled doses of antibiotics, then a 1 gram dose of ciprofloxacin (i.e., double 
oral dose or equivalent for another antibiotic) will be administered prior to discharged, to reduce 
the risk of infectiousness to the general community ; remaining doses to  complete a total of 3 days 
of therapy will be provided to the participant prior to “early discharge” .  Instructions for outpatient 
follow -up will be provided at the time of “ early discharge”, with the intent to continue all protocol -
described outpatient v isits, for the purpose of collecting safety information and the collection of 
research specimens.  Participants will ultimately decide on what amount of follow -up and safety 
or research specimens can/will be collected, upon their withdrawal  or their decisio n to terminate 
participation in the study.  
Handling of Participant Withdrawal  or Termination . Every effort will be made to undertake 
protocol -specified safety follow -up procedures to capture AEs, serious adverse events (SAEs), 
and unanticipated problems (U Ps). In the event of withdrawal or termination from the study, 
reasonable efforts should be made to conduct the following procedures:  
• Review diary card/ memory aid if still in use prior to withdrawal  
• Updat e any ongoing AE/SAEs that remain ongoing at time of subject’s last visit prior to 
withdrawal  
• Query about AEs, SAEs and concomitant medications if the interval between the subject’s 
last visit and the time of withdrawal is within the protocol defined report ing period  
• Perform p hysical examination  
• Obtain b lood for safety laboratory testing if withdrawal occurs before the day 36 visit  
• Update contact information  
Premature Termination or Suspension of Study . This study may be temporarily suspended or 
prematurely terminated if there is sufficient reasonable cause. Written notification, documenting 
the reason for study suspension or termination, will be provided by the suspending or terminating 
party to the PI, University of Maryland Baltimore Institutional Review B oard ( UMB IRB ), Institut 
Pasteur, funding agency  (BMGF), independent data and safety monitoring board  (DSMB ), and 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
28 the U.S. FDA (as the  regulatory authorit y). If the study is prematurely terminated or suspended, 
the PI will promptly inform the IRB and will  provide the reason(s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of clear efficacy that would warrant stopping  early (e.g., if there is near 
100% efficacy in the first two cohort challenges, then the third cohort could be suspe nded)   
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable (e.g., if loses were so excessive 
that the target number of challenges cannot be achieved in the three planned coho rts) 
• Determination of futility  
The s tudy may resume once concerns about safety, protocol compliance, and data quality are 
addressed and satisfy the IRB , DSMB , and FDA.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
29 5 STUDY PRODUCTS  
5.1 Study Vaccine, SF2a -TT15  
The key component in SF2a -TT15 is the fully syntheti c OS mad e of 15 monosaccharide residues, 
correspond ing to three non O -acetylated biological RUs  of the S. flexneri  2a O -Ag. It is therefore 
named either 15mer , Sf2aOS3,  or [AB(E)CD]3, whereby A, B and C are α -linked L -
rhamnopyranosyl residues, D is a β -linked 2 -N-acetyl -2-deoxy -D-glucopyranosyl residue ( N-
acetyl -D-glucosamine) and E is an α -linked D -glucopyranosyl residue.  The conjugation chemistry 
used for the synthesis of SF2a-TT15 involves the construction of a thioether linkage between the 
spacer-equipped  15mer OS and a maleimide -activated TT (TT Mal). The manufacturing , including 
all the conjugation chemistry , was performed under GMP conditions at Intravacc (Bilthoven, the 
Netherlands) .  
One dose (0.5 m L) of vaccine contains after dilution wit h aluminum hydroxid e adjuvant 
(Alhydrogel®, Brenntag, Denmark) the following components:  
• SF2a synthetic 15mer OS , 8.8 μg  
• Tetanus  toxoid, 29.1 μg  
• Al3+, 0.680 mg  
• Excipients: Tris(hydroxymethyl)aminomethene, Sodium chloride , and water for injection  
The SF2a -TT15 vaccine  is to be stored at 2 -8 °C, do not freeze.  The SF2a -TT15 vaccine (0.5  mL) 
and adjuvant (0.8 mL) are filled in 3 -mL hydrolytic type 1 glass (Ph.Eur) vials, sealed with a 
bromobutyl rubber stopper, and an aluminum crimp cap with polyprop ylene flip -off cap. The SF2a -
TT15  vaccine  is a clear colorless liquid and the adjuvant is a white turbid liquid after 
homogenization. The SF2a -TT15 vaccines are packed as a kit with the adjuvant vial.  
5.1.1  Preparation of Vaccine  Dose s for  Administration  
The fin al study product for administration is obtained by mixing 0.5 mL of adjuvant with 
0.5 mL of SF2a -TT15 vaccine.  Adjuvant will be drawn up with a disposable syringe and 
added to the vial with SF2a -TT15 , then the diluted SF2a -TT15 vaccine must be shaken 
gently for 1 minute before use.  A 0.5 m L volume of the diluted SF2a -TT15 vaccine will be 
drawn up to a separate disposable syringe for intramuscular  administration . The diluted 
study product vial can be used up to 4 hours , if stored at 2 -8 °C, or up to a maxi mum of 
30 minutes if kept at room temperature.  Prepared diluted vaccine must be  manually 
shaken gently before using. Once the mixed vaccine has been drawn into a syringe, it 
should be administ ered immediately  (within 30 minutes) .  Any unused vaccine or wa ste 
material should be disposed of in accordance with local requirements.   
5.2 Placebo, Sterile Saline  
The placebo is commercially -available physiologic sterile saline.  
5.2.1  Preparation of Placebo Doses for Administration  
The masked placebo consists of 0.9% sterile Sodium Chloride (normal saline), United 
States Pharmacopeia ( USP) grade. The saline vials are to be stored at room temperature 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
30 (20-25 °C). A 0.5 mL volume of normal saline will be drawn into a disposable syringe for 
intramuscular administration.  
5.3 Study Product Accountability  
The study product will be stored in and dispensed by the University of Maryland Medical Center 
(UMMC)  Investigational Drug Service (IDS) pharmacy. The FDA requires accounting for the 
dispositi on of  all investigational products. The Investigator is responsible for ensuring that an 
accurate record  of product disposition is maintained and product is dispensed only by authorized 
personnel as  required by applicable regulations and guidelines. Record s of product disposition 
as required by  federal law consist of the date received, date administered, quantity administered, 
and the  subject number to whom the study product  was administered.  The investigational 
pharmacist will be responsible for maintainin g accurate records of the  shipment and accountability 
of the study product. The preparation and dispensing of the study product  is performed by the 
IDS Pharmacy and the dosing of subjects is performed by CVD research staff ; the process and 
procedures are  documented and maintained  in a secure location that is segregated from the 
blinded research staff . The pharmacy records (both IDS pharmacy and CVD)  will be made 
available for inspection by external monitors and by the relevant regulatory  agencies (e.g., FDA ) 
at any time.  
5.4 Masking of the Study Product  
A prospectively assigned vaccinator and checker will be designated as unblinded personnel and 
will not have any role in the management of illness or assessment of AEs in study participants.  
Unblinded personnel w ill be responsible for the preparation of the study products and for the 
blinded labeling of the study products. The unblinded staff  will be responsible for maintaining the 
randomization key and will secure these study documents in a locked cabinet.  
The PI  or the Data and Safety Monitoring Board must submit a written request, to inform each 
other, for emergency unblinding, if this were to be performed. The written request must clearly 
state the justification for the emergency unblinding and describe which s pecific participants are to 
be unblinded. This document will be filed in the study regulatory file.  
5.5 Challenge Agent, S. flexneri  2a strain 2457T  
GMP m aster cell banks (MCB s) of S. flexneri  2a strain 2457T were produced by the Bioproduction 
Facility of the  Walter Reed Army Institute of Research (WRAIR, Forest Glen, MD). Long -term 
storage of the challenge inoculum MCB vials is at -80°C or colder.  
5.5.1  Preparation of Challenge Inoculum  
The challenge inoculum is prepared from a frozen MCB vial , which is plated onto TSA 
containing Congo red dye (0.01%). After incubation at 35 °C for 18 -24 hours, single, 
isolated colonies that exhibit characteristic Shigella  morphology and that are Congo red  
positive are to be confirmed as S. flexneri  2a using specific monoclonal type II and group 
3, 4 Shigella  antisera. Several well -isolated Congo red colonies will be picked and 
emulsified in sterile saline. The saline is then used to inoculate, for heavy gr owth, TSA 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
31 plates that are incubated overnight at 35˚C. Overnight growth from the TSA plates is then 
harvested into sterile phosphate buffered saline (PBS), pH 7.4 and washed 3 times. The 
heavy Shigella  suspension is diluted with additional sterile PBS to p roduce a suspension 
with an optical density (OD) at 660 nm corresponding to the desired bacterial count per 
mL—i.e., target dose of 1500 cfu . To determine the actual inoculum of challenge strain 
ingested, replicate colony counts will be performed pre - and post-challenge. The inoculum 
will be delivered to the study site on wet ice and used within 4 hours of preparation.  
5.5.2  Preparation of Bicarbonate Buffer  
Sodium bicarbonate (NaHCO3) is a white, crystalline powder that has a molecular weight 
of 84.01 gram/Mol and meets USP standards. This product comes in a 500 g plastic 
container and is stored at room temperature .  For each challenge inoculum to be ingested, 
a buffer solution will be prepared by mixing 2 g sodium bicarbonate with 150 mL 
nonbacteriostatic sterile water.  A 30 mL aliquot of the buffer solution will be set aside for 
the administration of the challenge agent  
5.5.3  Administration of Challenge Agent to Participants  
The challenge agent is to be administered orally in a buffer solution. Each subject will drin k 
120 mL of sodium bicarbonate buffer  solution. Approximately 1 to 2 minutes later, the 
subject will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 
mL of the bicarbonate buffer solution. Subjects should have no food or water f or 90 
minutes pre - and post -inoculation. Subjects will be observed during the 90 minutes  after 
challenge for retention of the challenge inoculum and any immediate AEs/SAEs.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
32 6 STUDY PROCEDURES/EVALUATIONS  
6.1 Study Procedures  
Informed Consent . All aspects of the protocol will be explained in depth to subjects.  Subjects who 
provide informe d, written consent will be screened for eligibility.  To evaluate comprehension of 
the study and to document that informed consent has been obtained , all subje cts must pass a 
written examination before vaccination , Comprehension Assessment Tool .  The exam contains 
approximately 2 0-25 multiple choice and true -false questions on all aspects of the protocol.  Staff 
will review incorrect answers with the subject.  A  subject who scores below 70% may take the test 
a second time but will be excluded if a passing  score  ≥ 70% is not obtained . 
Medical Screening . After signing the consent form, verification of Notification of Privacy Practices 
(NPP) receipt, and HIPAA autho rization  forms will be completed. S ubjects will undergo a clinical 
evaluation to ensure that they are in good mental and physical health, which will include a medical 
history, vital signs, and a brief physical examination (oral cavity, auscultation of hear t and lungs, 
abdominal examination, lymph nodes) . Blood will be drawn for a  complete blood count with 
differential  (WBC, ANC, hemoglobin, platelets) , blood chemistries ( creatinine, ALT, total bilirubin) , 
serological test for HIV, hepatitis C , hepat itis B s urface antigen, serum IgA, HLA-B27 typing , and 
a S. flexneri  2a LPS ELISA titer .  Urine will be collected for a urinalysis. A stool sample will be 
collected for bacterial culture (for Salmonella , Shigella , Campylobacter , Yersinia , and V. 
cholerae ), prior to challenge .  Serum pregnancy test in females of child -bearing potential must be 
negative during screening and a urine pregnancy test must be negative within 24h of each 
vaccination. A 12-lead electrocardiogram will be performed.  
Subjects who are ex cluded based on screening results will be counseled by the clinical staff and 
referred for medical care, as appropriate. If elevated blood pressures are detected after 
enrollment, the investigator will make a determination whether continued participation w ould be 
unsafe or would interfere with the study evaluations.   
Blinded Vaccination . The vaccine and placebo will be administered by the IM route by needle and 
syringe . To maintain the blind, a member of the investigative team who will not be involved in the 
clinical evaluation of the subjects will be responsible for preparing and labeling the vaccine and 
placebo with a randomized number.  An unblinded checker will be present to verify that the correct 
randomization scheme has been followed.  
Acclimatization  for Challenge Phase . Study participants will begin  the Challenge phase with 
admission to the inpatient unit for  2 days of acclimatization, during which time we observe for 
normal (grade 1 -2) stool patterns, we educate and familiarize each sub ject with the protocol -
required procedures (e.g., stool handling), hygiene practices, and the “Rules and Procedures” to 
be followed while on the inpatient unit.  In addition, during the acclimatization period, we monitor 
behavior, person -to-person interact ions, mood, etc. to assess each study participant for any 
behavior or attitudes which might not be appropriate for an inpatient study (i.e., combativeness, 
anti-social behavior, anger outbursts, destruction of property, etc.).  Any evidence that a subject 
may demonstrate behaviors which might pose a safety risk to themselves, other subjects, or staff 
could be cause for ineligibility for challenge  (whereupon these subjects are discharged prior to 
challenge administration) . Refusal to comply with protocol -required procedures, adherence to 
hygiene practices, or repetitive breaking of the “Rules and Procedures” could also constitute 
ineligibility.  This observation during the acclimatization period may be considered an imperfect 
and rather subjective method, but  we have not identified any other good alternate objective 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
33 measures that substitute for this direct observation procedure.  Any subject who is deemed 
ineligible will be discharged, prior to challenge . 
During the time when a U.S. Public Health Emergency for  COVID -19 exists, a SARS -CoV-2 
molecular diagnostic test will be performed on each participant upon admission to the inpatient 
unit. A negative test result and the absence of COVID -19 symptoms will be required for final 
eligibility for challenge . All subje cts must have completed COVID -19 vaccination at least 14 days 
prior to challenge.    
Inpatient Observation . Subsequent to challenge , participants will remain on the ward for 
approximately 10 days .  Vital signs and oral temperature will be measured at least every 8 ±1 
hours by staff nurses who remain on the ward 24h a day. All stools will be graded for consistency, 
loose stools (grade 3 or higher, diarrheal stools) will be weighed and the presence of blood will 
be confirmed by hemoccult test. Participants will be interviewed daily by a study physician to 
determine the occurrence of illness signs and symptoms (e.g., anorexia, malaise, abdominal 
cramps, headache) which occurred during the previous stu dy day; these data will be recorded on 
a standardized form and graded in severity according to a standardized scale.  A focused physical 
examination may be performed at the discretion of the physician according to the nature of a 
participant’s complaint.  
The 5th floor Research Isolation Ward  is located on Pharmaron  (800 W. Baltimore Street , 
Baltimore, Maryland)  and consists of a total of 48 beds, available as 3 bed dormitory  rooms and 
12 bed dormitory rooms and which allows for the space to have a flexible configuration for different 
study size requirements.  Each bed is provided with a privacy curtain. There are 10 toilets  on the 
ward. For enteric challenge studies, portable commodes are employed as needed and upon 
request, to be located adjacent to the bed side.  General ward rules and procedures are employed 
which includes a description of the expectation for maintaining privacy for all participants and for 
hygiene practices.  
Measurement of Diarrhea and Dysentery . Since diarrhea and/or dysentery are key measures of 
shigellosis , all participants will be expected to collect every stool that is passed, from the time of 
challenge  until discharge.  Participants will be instructed to use a plastic stool collection basin, 
commonly called a “ Napolean hat”.  All stools will be graded by the study staff.  The grading of 
stool is based on consistency and the definition of diarrhea is a g rade 3 or higher stool, as follows:  
• Grade 1 – well formed (normal stool, does not take the shape of the container)  
• Grade 2 – soft (normal stool, does not take the shape of the container)  
• Grade 3 – thick liquid (diarrhea, takes the shape of the container re adily)  
• Grade 4 – opaque watery diarrhea  
• Grade 5 – rice water diarrhea (clear watery)  
Any grade 3 or higher stool is considered a diarrheal consistency stool  and must be weighed, to 
estimate the volume of fluid loss (assume ~1 g diarrheal stool = 1 mL of fl uid lost).  Stools must 
be evaluated with a hemoccult test, for confirmation of dysentery.  
Similarly, any episodes of vomiting should be collected in either a stool “hat” or a plastic “kidney” 
basin, provided.  If a vomiting or diarrhea episode is not able  to be collected in a basin (e.g., the 
subject has an “accident” while sleeping or before they are able to reach a toilet), then the volume 
of the output will be estimated.  
Management of Fluid Losses . Subjects who develop diarrheal stools (grade 3 or highe r) during 
the inpatient observation will be required to ingest standard World Health Organization (WHO) 
Oral Rehydration Solution (ORS) at 1.5 times the stool volume. Vomitus will be replaced with 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
34 ORS in equal amounts, 1:1 ratio. At the discretion of the i nvestigator, additional ORS may be 
administered. If a subject develops severe watery diarrhea or persistent vomiting and cannot 
maintain full hydration by oral means, IV fluid replacement will be administered.   
For the duration of diarrhea, the subject wi ll be requested to provide a urine specimen  from every 
void that they experience; the specimen will be tested for urine specific gravity.  In the event that 
intravenous fluids are required, serum electrolytes (Sodium, Potassium, Chloride, Bicarbonate), 
BUN, and creatinine will be measured.   
A phys ician is available by telephone or beeper at all times. Nurses will notify the on -call physician 
if any of the following occurs in a subject who is experiencing diarrhea and/or vomiting:  
• Syncope  
• Complaint of dizziness or lightheadedness or established orthostatic hypotension  
• Urine specific gravity > 1.025  
• > 500 mL behind in ORS replacement  
• Vomiting of ≥ 500 mL once or total volume within the past 4 hours  
• High fever ≥ 39 C (102. 2F) 
• Severe headache, severe malaise, or severe abdominal pain  
• Subject has a complaint for which he/she requests treatment  
• Any other clinical situation that concerns the nurse  
Frequency of Vital Signs Assessment . Vital signs (blood pressure, pulse, and oral temperature) 
will be measured approximately every 8 hours, unle ss more frequent monitoring is needed. Once 
a subject has passed a diarrheal stool (grade 3 or higher), vital signs will be measured every ~4 
hours until the subject passes a grade 1 or 2 stool or 24 hours have passed since the last grade 
3 – 5 stool, whic hever comes first.  Vital signs will also be measured every ~4 hours when a 
subject has a fever ≥ 3 8C (10 0.4F), until the subject has 2 consecutive temperatures of < 38C 
(100.4F). Any subject that complains of dizziness or lightheadedness upon standing  will have 
orthostatic blood pressures assessed —BP after supine for ~5 minutes and BP after standing ~2 -
3 minutes. Orthostatic hypotension is defined as a drop in systolic BP > 20 mmHg or in diastolic 
BP > 10 mmHg.  
Fluid Therapy/Hydration . Oral Rehydration Solution (ORS) will be offered as the primary means 
of hydration.  ORS will be prepared according to the manufacturer’s package insert (Jianas Bros 
ORS).  Unused ORS should be discarded 24 hours after preparation.   
Intravenous fluids (Lactated  Ringers solution) will be administered to subjects with diarrhea who 
meet any of the following criteria:  
• Orthostatic hypotension  
• Urine specific gravity > 1.025, or determined as necessary by the Investigator  
• No urine output for ≥ 8 hours  
• > 1000 mL deficit  in ORS replacement  
• At the investigator’s discretion, based on clinical evaluation or on a subject’s difficulty in 
keeping up with ongoing diarrheal losses by oral rehydration alone  
Intravenous therapy will continue until the above criteria are no longer s atisfied, the subject is 
able to take fluid by mouth, and a study physician determines that it is no longer required.  
Indications for Antibiotics . Antimicrobials will be administered immediately if a subject meets one 
of the primary endpoints in the criteria described under Appendix E .  Otherwise, for challenge 
participants that do not meet criteria for early treatment with antibiotics, they are to i nitiate 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
35 antibiotic treatment 5 days ( 120 hours) after receiving the challenge. Antibiotics may also be 
initiated upon investigator judgement, for the safety or welfare of the participant.  
Antimicrobials will consist of a t least a  3 day course  of ciprofloxacin (primary , preferred treatment ) 
or trimethoprim -sulfamethoxazole (secondary , back -up option for treatment ). In rare and 
unexpected instances, the study investigator will be allowed to administer antimicrobials for 
alternate reasons —e.g., if in their judgment it is necessary to ensure the safety of the subject. 
Ciprofloxacin dosin g will begin with a 1000 mg loading dose followed by 500 mg doses 
administered every 12 hours (± 1 hr.). Trimethoprim (160 mg)/sulfamethoxazole (800 mg) every 
12 hours (± 1 hr ) for 3 days will be substituted in the event of an allergy or adverse reaction to 
ciprofloxacin. Ampicillin 500 mg by mouth every 6 hours (± 1 hr ) for 5 days will be administered 
in the unlikely event that a woman becomes pregnant.  
Indications for Other Concomit ant Medications .   The use of a ny such PRN medication s which 
are over -the-counter medications  will need to be discussed with and approved by the investigator 
prior to admission.  A single prescription medication that has been declared and reviewed upon 
admi ssion and which has received pre -approval from the investigator (for the medication and the 
condition it is treating) may be allowable. This prescription medication may be secured by the 
study team and access will be made available for subject self -dispens ing throughout the inpatient 
stay. Deviations from the prescribed dosage and/or frequency of the medication may be judged 
by the investigator as grounds for subject non -compliance or may constitute a violation of the 
ward “Rules and Procedures.” Otherwise , the eligibility criteria forbid the use of two or more 
chronic concomitant medication use.   Any un -declared prescription or over -the-counter 
medications that are discovered during the inpatient stay will constitute a violation of the ward 
“Rules and Proce dures.”  
Other medications may be administered during the study period as follows:  
• Smoking is not allowed on the ward, but subjects will be able to request nicotine patch es.  
• Anti-pyretics and analgesics (i.e., ibuprofen, acetaminophen, aspirin, or similar non-
steroidal agents) may be prescribed for severe headaches, other pains, or fevers (e.g., 
sustained temperatures of ≥ 102.2F or 39C).   
• At the investigator’s discretion (e.g., upon review of serum electrolyte results during severe 
diarrhea), oral potassium may be administered for repletion of electrolyte losses.  
• Other medications, which are deemed necessary for the safety and welfare of the subject  
The prescription of any medication (except the pre -approved single prescription medication 
mentioned  above) must be ordered and signed by the investigator and each administration 
recorded.  Verbal orders are allowable and are to be recorded by the nurse and signed by the 
ordering physician within 24 hours.  
Stool Microbiology . Stool cultures for identifica tion of Shigella will be performed to characteriz e 
the pattern of fecal shedding . After challenge, a ll stools will be collected, graded, and weighed 
while volunteers are on  the Research Isolation Ward. Qualitative and quantitative cultures will be 
performe d on the first t wo stool samples of each 24 hour period . Once antibiotics are initiated, 
qualitative culture only will be performed. During the outpatient follow up visits within 1 week of 
discharge (visit 6), 1 month after challenge (visit 7) and last visit (visit 9), stool will be collected for 
qualitative culture to ensure no presence of Shigella ; should Shigella  be identified, then a repeat 
3-day course of antibiotics will be required for that participant.  If a person is unable to produce a 
stool by near midnight (a 24 hour period), then a rectal swab will be performed for qualitative 
culture only . Note:  the exception is the screeni ng stool culture, which is to be evaluated through 
a CLIA -approved clinical laboratory and is intended to rule out the presence of enteric pathogens.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
36 In place of the screening stool culture , as performed by standard bacteriologic culture methods, 
it is als o acceptable to use a CLIA -approved molecular diagnostic test to rule out the presence of 
enteric (e.g., BioFire FilmArray GI Panel).  
Shigella  Disease  Severity Scoring .  Using clinical data that is planned to be collected by the 
investigator during the challenge phase, a n ordinal disease scoring system will be used to 
characterize the disease elicited by the challenge model, using a previously published method.44 
The s coring of disease severity consist s of several parameters, including objective signs, 
subjective symptoms, and loose stool (grade 3 or higher) output over 24 hours . The signs, 
symptoms, and loose stools from the time of challenge and through 24 hours after the initiation of 
antibiotics wil l be used in the Shigella  Disease Severity Scoring system.  
For objective signs, each of the following adds one point to the score: Gross blood in ≥2 loose 
stools (hemoccult confirmed), maximum temperature >101.1 °F, any vomiting.   
Subjective symptoms are based on the severity (severe: prevents routine activity; moderate: 
some interfere nce with routine activities; mild: does not interfere with routine activities) of 
arthralgia, nausea, myalgia, headache, anorexia, abd ominal  cramps/pain.  If more than one of 
those subjective symptoms is coded as severe the subject will have a subjective symptom score 
of 3, if only one is coded as severe, their score is a 2, and if the subject has multiple moderate 
symptoms (but none is coded as severe), their score is a 1. If the subject has only one moderate 
(or only mild or no symptoms), it is 0.  Loose stool output is coded as follows based on the 
maximum 24 hour output: score of 0 for ≤1 loose stool in 24 hrs, score of 1 for 2-3 loose stoo ls in 
24 hrs, score of 2 for 4-8 loose stools in 24 hrs; and score of 3 for ≥9 loose stools in 24 hrs.  Total 
Shigella  Disease Severity Score s may range from 0 -9.   
All the elements which  contribute to the Shigella  Disease Severity Score are obtained from data 
that is collected by the study team (i.e., there will not be additional subject self -reporting through 
questionnaires to collect these data) ; see Appendix F  for the collection of subjective symptoms .  
Shigella  Disease Severity Scoring  
Parameter  Outcome  Score  
Objective signs  Gross blood in ≥2 loose stools (hemoccult confirmed)  1 
Maximum temperature (°F); >101.1  1 
Vomiting  1 
Subjective symptoms  More than one of the following as severe: arthralgia, nausea, 
myalgia, headache, anorexia, abd cramps/pain  3 
Any one of the following as severe: arthralgia, nausea, myalgia, 
headache, anorexia, abd cramps/pain  2 
More than one of the following as moderate: arthralgia, 
nausea, myalgia, headache, anorexia, abd cramps/pain  1 
Loose stool output  
(max 24 hr freq)  0-1 0 
2-3 1 
4-8 2 
≥9 3 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
37 6.2 Laboratory Evaluations  
6.2.1  Laboratory Evaluations/Assays  
Screening  Clinical  Laboratory . The following clinical laboratory assessments will be 
performed as part of the screening for eligibility  (Appendix B ): 
• CBC with differential for total white blood cell count (WBC), absolute neutrophil 
count (ANC), hemoglobin (Hg), platelet count  
• Creatinine, a lanine amino trans ferase  (ALT), total bilirubin  
• Serum IgA  
• Hepatitis B surface antigen, Hepatitis C virus antibody, HIV  
• β-HCG (if woman of child -bearing potential)  
• HLA-B27 histocompatibility testing  
• Urinalysis for glucose, p rotein, and occult blood  
• Stool culture  or BioFire FilmAr ray Gastrointestinal (GI) Panel (or equivalent CLIA -
approved molecular diagnostic test)  – eligibility for challenge not vaccination  
 
For clinical laboratories to be evaluated, the following tubes may be used:  
• 4 mL EDTA for CBC with differential  
• 8.5 mL tiger top for chemistries, serum IgA, HBsAg, HCV, β-HCG  
• 4 mL EDTA for HLA -B27 test  (Monday through Thursday shipments only)  
• 3.5 mL tiger top for HIV test  
Screening S. flexneri  2a LPS IgG titer . Approximately 5 mL of whole blood will be collected 
for serum. The standardized serum S. flexneri  2a LPS  IgG ELISA will be performed, as 
per the previously published methodology.45  Screening titers are calculated as the inverse 
of the serum dilution. Subjects with screening tite rs of >2500 will be excluded from the 
study.  
12-lead Electrocardiogram (ECG) . A standard 12 -lead ECG will be performed as part of 
screening for eligibility. Pathological abnormalities will be exclusion criteria, as described 
in Appendix B . 
Safety Laborator y. The following clinical laboratory assessments will be performed at the 
Day 36 visit (grading of toxicity is according to Appendix C ): 
• CBC with differential for total white blood cell count (WBC), absolute neutrophil 
count (ANC), hemoglobin (Hg), platelet count  
• Creatinine, a lanine amino trans ferase (ALT), total bilirubin  
Stool for Culture  During Acclimatization . A stool culture will be conducted from a stool 
specimen provided during the acclimatization. The results may not need to be available 
for challenge and are intended to definitively document the absence of enteropathogens 
prior to challenge.  
6.2.2  Special Assay s or Procedures  
ELISA  Antibody in Serum, Urine, and Stool . Serum , urine, and stool  antibody  responses 
will be measured against  S. flexneri  2a LPS. Standardized ELISAs for immunoglobulin G 
(IgG) and immunoglobulin A (IgA)  will be used to quantify antibody responses.33,46 -48  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
38 ELISA t iters will be  calculated as the inverse serum dilution that  produces an absorbance 
value (405 nm) of 0.2 above background . ELISA for serum and urine antibodies to S. 
flexneri 2a LPS will be performed at Tel Aviv University (Prof. Dani Cohen) . ELISA for 
serum  antibodies to S. flexneri 2a LPS will be performed  at WRAIR (Dr. Robert Kaminki) 
and CVD (Dr. Marcela Pasetti) . 
Serum Bacterici dal Antibody (SBA) . The functional activity of immune sera will be 
analyzed using the serum bactericidal antibody ( SBA).49 SBA titers are calculated from 
the reciprocal of the serum dilution that produce s 50% bacterial killing . The SBA tests will 
be performed at Tel Aviv University (Prof. Dani Cohen).  
Antibody -Secreting Cells (ASC) . Plasmablasts secreting antibodies that recogniz e S. 
flexneri  2a LPS will be measured using ELISPOT.33,46 The frequency of spot -forming cells 
(SFC) from replicate  wells will be determined and reported as ASC/106 PBMC. A positive 
response will be defined as ≥8 ASC/106 PBMC.  
Antibodies i n Lymphocyte Supernatants (ALS) . ALS supernatant fluid will be collected and 
tested in an ELISA assay to measure antigen -specific IgA and IgG antibodies released by 
the PBMC.50  Endpoint titer s will be  calculated as the reciprocal dilution giving rise to an 
absorbance value of 0.4 above the background at 450 nm. A  positive response will be 
defined as a ≥4-fold increase in ALS titer over baseline.  
ASC Homing Studies . To measure the homing potential of plasmablasts,  PBMC will be 
enumerated by flow cytometry based on molecules expressed in naïve (B n; CD19+ IgD+ 
CD27 -) and memory B (B M; CD19+ IgD- CD27+ ) cells which direct the m to hom e to distinct 
sites (e.g., integrin α4β7, CD62L , CXCR3 ).51 Several o f these populations (e.g., B n, B M 
expressing combinations of CXCR3, integrin α4β7 and/or  CD62L] will be sorted and their 
ability to secrete specific anti -S. flexneri  LPS antibodies will be determined by ELISPOT 
as described for ASC determinations . Sorting  will be performed using a MoFlow Astrios 
EQ flow cytometer/cell sorter state -of-the-art system available in the CVD Flow Cytometry 
and Mass Cytometry Core Laboratory.  
Qualitative/Qua ntitative Stool Culture . For each stool specimen, a sample of the “whole 
stool,” will be placed in a sterile specimen container  and then kept for short -term storage 
at 2-8°C. A sterile cotton swab (or the rectal swab) will be inserted into the stool (sampling 
nearest the most loose or liquid parts of stool or areas with gross blood) and then placed 
into a tube containing BGS transport medium  for short -term storage at 2-8°C. The CVD 
Microbiology Lab will plate the “whole  stool ” specimen for quantitative culture of S. flexneri  
2a strain , and  will plate the stool in BGS for qualitative culture of S. flexneri  2a strain. S. 
flexneri  2a strain will be confirmed  by agglutination with commercial typing antisera . 
Stool Cytokine Analysis . For each day post -challenge  (days 57 -64), a single 
representative stool from each challenge par ticipant will be used to assess calprotectin 
and myeloperoxidase (MPO). Whole stools will be collected and placed into sample 
collection containers, as provided by the commercially available kits to be purchased 
from Epitope Diagnostics, Inc. (San Diego, C A): KT -849 for quantitative fecal 
calprotectin ELISA kit and KT -844 for the fecal MPO sample collection kit.  This assay 
will be performed at WRAIR, Department of Subunit Enteric Vaccines & Immunology (Dr. 
Robert W. Kaminiski).         
Future Studies . Stool  for microbiome (e.g., 16S rRNA profiling) and transcriptomics, 
blood transcriptomics, serum microarray, or other analyses which would be for the 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
39 characterization of responses to vaccination or challenge may be performed in the future 
on banked specimen.  
6.2.3  Specimen Collection, Preparation, Handling and Shipping  
6.2.3.1   Instructions for Specimen Preparation, Handling, and Storage  
Instructions for specimen preparation, handling, and storage are described in the  
Manual of Procedures  (MOP ). 
6.2.3.2  Specimen Shipment  
Clinical laboratory specimens will be shipped to collaborators at Tel Aviv University 
(Israel) , Walter Reed Army Institute of Research (Silver Spring, MD) , and Institut Pasteur 
(Paris, France)  for immunological analysis  as outlined in the MOP . Research stu dy 
specimens are intended to be stored until complete use for future -use research.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
40 7 STUDY SCHEDULE  
Complete study schedule details listed by type of visit are described below. Refer also to 
Appendix A: Study Schedule of Events .  
7.1 Screening  (-60 to -1 days prior to enrollment)  
Potential volunteers may be screened for eligibility up to 60 days prior to enr ollment. Interested 
potential participants, responding to advertisements, campus flyers, or notification through 
existing databases, will be instructed to call the CVD to receive further information about the 
study. CVD research staff receives these inquir ies and read through an IRB -approved telephone 
script which describes basic information on the study topic, duration and number of visits, 
procedures, and eligibility criteria. No personal health information is solicited and afterwards 
interested potential  participants can be given an appointment to attend an Orientation Session  for 
formal screening.  
At the Orientation Session , the consent process continues. CVD research staff will provide a 
detailed description of all aspects of the study, including the rationale and background, the public 
health significance, the procedures and schedule of visits, and a detailed discussion of  the risks 
and the presence or absence of benefit to them, as appropriate. This Orientation Session  is 
commonly one hour long. The prospective subject is given a copy the study consent form (without 
the signature page) and is encouraged to discuss his/her participation with family members or 
advisors before agreeing to sign the informed consent form and proceeding with any screening 
procedures.  
After the informed consent form is signed, the subject is interviewed one -on-one by a member of 
the study team to  discuss the study. A brief written examination is administered to assess the 
volunteer’s comprehension of the study (i.e., Comprehension Assessment Tool ). If this quiz is 
passed (≥70% correct answers), the research staff complete the medical history and c oncomitant 
medication forms, draw blood for eligibility testing, and obtain an ECG. Study subjects are also 
asked to sign a verification of Notification of Privacy Practices receipt and Health Insurance 
Portability and Accountability Act (HIPAA) authorizat ion form. The subject also meets the PI, or 
designee, and has a physical examination to complete the eligibility screening. If the subject has 
passed all the eligibility criteria, he/she is then invited to proceed in the study and is given an 
appointment f or the next visit.  The screening procedures may be completed in a single day or on 
multiple days, as long as the screening procedure dates do not exceed 60 days prior to 
vaccination . 
It is recognized that volunteer studies must be carried out in an enviro nment where no coercion 
is applied, and where volunteers can be adequately informed of the purpose, nature, procedures, 
risks and hazards of the study. To assess and document comprehension of the material 
presented, each subject must pass a written quiz (s core 70% or higher) containing approximately 
20 multiple choice and true/false questions covering all aspects of the study including the purpose, 
procedures, risks, benefits and pertinent microbiology. Incorrect answers will be reviewed with 
the subject. T he quiz may be retaken once, after a review of the consent form. The 
Comprehension Assessment Tool  is dated and signed by the subject and by a research staff 
member and made part of the permanent record.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
41 Another important feature of our consent process is  the repeated demonstration of both initiative 
and reliability by the prospective subject. There are multiple opportunities for the subject to decline 
to proceed further in the process. This deliberate education and screening process contributes to 
the inf ormed nature of the subject’s consent. The process also increases the likelihood that the 
subject will be committed to completing the entire inpatient containment portion of this study. 
Prospective subjects will be carefully screened to ensure that they ar e in good physical and mental 
health.  
The screening procedures include:  
• Signed, witnessed informed consent  
• Administration of the study Comprehension Assessment Tool  
• Obtaining vital signs (oral temperature, blood pressure, pulse, height, and weight)  
• Colle ction of medical history  
• Collection of concomitant medication history  
• Perform physical examination, to be performed by a study clinician  
• Perform 12 -lead electrocardiogram (ECG); the interpretation of screening ECG eligibility 
is defined in Appendix B . 
• Obta in the following screening laboratory studies (~2 5 mL blood); the acceptable values 
for the screening laboratory tests are defined in Appendix B : 
o Complete Blood Count (CBC) with differential and platelet count for the 
evaluation of WBC, ANC, Hemoglobin, an d Platelets  
o Creatinine, ALT (SGPT), and Total Bilirubin  
o Serum IgA  
o Serum Sf2a LPS IgG  
o HLA-B27 histocompatibility  
o Urinalysis for the evaluation of glucose , protein , and blood  
o Pregnancy test (if female  of child -bearing potential, serum β -HCG)  
o HIV antibody  
o Hepatitis B surface antigen  
o Hepatitis C antibody  
Note: Since intravenous fluids is a part of the planned management of severe diarrhea, if  more 
than 3 attempts at venipuncture are required for obtaining screening labs, then we will consider 
that p erson in eligible on the basis of poor venous access.  
7.2 Visit 1 - Enrollment and Vaccination Dose #1 (Day 1)  
Study volunteers that have been determined to be eligible for participation through screening will 
be scheduled for enrollment. Upon arrival to the o utpatient research clinic, each study participant 
will have the following procedures performed:  
• Confirmation o f ongoing consent  
• Review of changes to medical history, concomitant medications, travel history  
• Vital signs assessment (oral temp, blood pressure,  pulse)  
• Physical examination, if indicated  
• Review and a ffirmation of eligibility criteria  
• For women of childbearing potential, urine pregnancy test  
• For Cohorts 1 -3: 
o Collection of stool sample, at least 5 grams  
o Collection of urine sample, at least 20 mL  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
42 o Collection of venous blood sample, 15 mL in serum separator tube s and 110 mL 
in EDTA vacutainers  
Enrollment and randomization may be performed after eligibility has been confirmed.  Once 
randomization has been completed, the participant  will receive a single dose of blinded study 
product per randomized assignment via IM injection in the deltoid muscle of the preferred arm .   
• After vaccination, s ubjects will be observed in the clinic for at least 20 minutes .  The 
vaccination site will be examined, and any AE/SAEs will be assessed prior to discharge 
from the clinic.  
• Subjects will be provided with a Memory Aid document and will be instructed on how to 
use the memory aid and how to measure and record AE/SAEs pr ior to discharge from 
the clinic.  
• A digital thermometer will be provided for the assessment of daily oral temperatures; 
subjects will be encouraged to take their temperature around the same time each day.  
• Subjects will be instructed to notify the study c enter if they develop any severe reactions 
following vaccination  
7.3 Visit 2 – Clinic Follow -up Post -Dose #1 (Day 8, +1  day window)  
• Confirmation o f ongoing consent  
• Vital signs assessment (oral temp, blood pressure, pulse)  
• Physical examination, if indicated  
• Collect and review the information on the Memory Aid document  
• Review for any unsolicited AEs and concomitant medications  
• For Cohorts 1 -3: 
o For participants in the Homing Studies Subset , collection of venous blood  
sample, 15 mL in serum separator t ubes and 50 mL in EDTA vacutainers  
o For those not in the homing subset, collection of venous blood sample, 15 mL in 
serum separator tubes and 20 mL in EDTA vacutainers  
• Provide stool collection kit and instructions  for next clinic visit  
7.4 Visit 3 – Vaccination  Dose #2 (Day 29, ±2 day window)  
• Confirmation of ongoing consent  
• Review of changes to medical history, concomitant medications, travel history  
• Vital signs assessment (oral temp, blood pressure, pulse)  
• Physical examination, if indicated  
• Review and affirmati on of eligibility criteria  
• For women of childbearing potential, urine pregnancy test  
• For Cohorts 1 -3: 
o Collection of stool sample, at least 5 grams  
o Collection of urine sample, at least 20 mL  
o Collection of venous blood sample, 15 mL in serum separator tubes and 110 mL 
in EDTA vacutainers   
Once confirmation of eligibility of vaccination has been completed, the participant  will receive a 
single dose of blinded study product per randomized assignment via IM injection in the deltoid 
muscle of the preferred arm .   
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
43 • After vaccination, subjects will be observed in the clinic for at least 20 minutes.  The 
vaccination site will be examined, and any AE/SAEs will be assessed prior to discharge 
from the clinic.  
• Subjects will be provided with a Memory Aid d ocument and instructed on how to record 
AE/SAEs  
7.5 Visit 4 – Clinic Follow -up Post -Dose #2 ( 7 days post -2nd 
vaccination , +1 day window)  
The timing of this visit is intended to be approximately Day 36 but is intended to be flexible 
because of the dependence of  this visit according to the receipt of the second dose of vaccine.  
• Confirmation of ongoing consent  
• Vital signs assessment (oral temp, blood pressure, pulse)  
• Physical examination, if indicated  
• Collect and review the information on the Memory Aid document  
• Review for any unsolicited AEs and concomitant medications  
• Collection of clinical safety laboratory, 4 mL in purple top tube and 3.5 mL in red top tube  
• For Cohort 1 -3: 
o For participants in the Homing Studies Subset , collection of venous blood 
sample, 15 mL in serum separator tubes and 50 mL in EDTA vacutainers  
o For those not in the homing subset, collection of venous blood sample, 15 mL in 
serum separator tubes and 20 mL in EDTA vacutainers  
• Collection of a stool sample for s tool culture or BioFire FilmArray Gastrointestinal (GI) 
Panel (or equivalent CLIA -approved molecular diagnostic test) . This is being performed 
as a screening procedure prior to challenge. This procedure is allowed to be collected 
with a +21 day window . 
7.6 Inpatient Containment Perio d (~Day 55 -66, or challenge timed to 
be ~28 days post -2nd vaccination ) 
Study participants that have received two doses of blinded study product and are available for the 
challenge phase may be scheduled for admission to the inpatient containment unit (rese arch 
isolation ward). The timing of the inpatient and challenge is intended to be approximately 28 days 
(+7 days window) from the completion of the second dose of vaccine. The anticipated duration of 
the inpatient stay is 12 days . 
7.6.1  Acclimatization ( 2 days prior to challenge ) 
Study participants will start their inpatient stay with 2 days for acclimatization, during which 
we educate and familiarize each subject with the protocol -required procedures (e.g., stool 
handling), hygiene practices, and the “Rul es and Procedures” to be followed while on the 
inpatient unit.   
An important aspect of the acclimatization period is the performance of a psychological 
evaluation  which is intended to reduce the risk of problems with subject compliance and 
potential risks  to the safety and welfare of participants .  In the past, a contracted 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
44 psychiatrist performed a formal psychological evaluation of mental health on each 
participant prior to challenge. This approach was expensive, time -consuming, and was not 
entirely adequ ate for predicting the appropriateness  of an individual for an inpatient stay.  
Therefore, the approach, which is currently in use, is an informal psychological evaluation. 
During  the 2-day acclimatization period, we closely monitor behavior, person -to-person 
interactions, mood, etc. to assess each study participant for any behavior or attitudes that  
might not be appropriate for an inpatient containment study (i.e., combativeness, anti -
social behavior, anger outbursts, destruction of property, etc.).  Any e vidence that a 
subject may demonstrate which might pose a safety risk to themselves, other subjects, or 
staff could be cause for ineligibility for challenge  and the remainder of the inpatient stay. 
Refusal to comply with protocol -required procedures, adher ence to hygiene practices, or 
repetitive breaking of the “Rules and Procedures” could also constitute ineligibility  through 
our informal psychological evaluation .  This informal psychological evaluation during the 
acclimatization period may be considered a n imperfect and rather subjective method, but 
we have not identified any other good alternate objective measures that substitute for this 
direct observation procedure. The psychiatrist -generated formal psychological evaluations 
were not a better predictive  tool than the direct observation approach.  Nonetheless, all 
participants will be provided the opportunity to discuss with a psychologist before entering, 
during inpatient containment , and after discharge if he/she wishes . Any subject who is 
deemed inelig ible will be discharged, prior to challenge , and back -up eligible participants 
will be used . 
At any time during acclimatization (prior to ingestion of challenge), the following will be 
collected:  
• Stool specimen, for stool culture , fecal IgA, transcriptomic , microbiome  
• Urine specimen, at least 20 mL  
• Venous blood specimen, 15 mL in serum separator tubes, and 110 mL in EDTA 
vacutainers  
• During the period when a U.S. Public Health Emergency exists, a SARS -CoV-2 
molecular diagnostic test will be performed, which must be a negative test result 
prior to challenge  
7.6.2  Challenge   
On the morning of challenge , subjects will have baseline vitals (oral temperature, pulse, 
and blood pressure) recorded and a final eligibility confirmation will be completed prior to 
oral ingesti on of the challenge inoculum .   
After confirmation of at least 90 minutes of f asting , eligible subjects will drink 120 mL of 
sodium bicarbonate buffer solution (~1.3% NaHCO 3); approximately 1 -2 minute s later, 
subjects will ingest the challenge inoculum consisting of ~1500 cfu of strain 2457T 
suspended in 30 mL of sodium bicarbonate buffer solution .  Subjects will have nothing by 
mouth, for 90 minutes before and after ingestion of the blinded study produ ct. For the 90 
minutes after challenge, participants will be observed for any immediate AEs. 
All back -up study participants that are not challeng ed will be discharged from the inpatient 
ward upon the completion of the target number of challenge recipients .    
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
45 7.6.3  Post -Challenge  Observation Period ( until  discharge)  
For the remainder of the inpatient stay , study participants will be observed on the 
Research Isolation Ward and the following procedures will be performed:  
• All stools will be graded for consistency (g rade 1 -5) and any diarrheal stool (grade 
3 or higher) will be weighed.  We assume a 1:1 weight per volume conversion for 
diarrheal stools. Blood from each  stool specimen will be confirmed to have  blood 
with a hemoccult test.  Up to two stool specimens per d ay will be submitted for 
culture.  
• Any vomitus will also be weighed.   
• Vital signs will be measured at least 3 times daily (approximately every 8 hours).  
• For each day , the maximum of an adverse symptom over that day will be assessed.  
The solicited a dverse symptoms include: nausea, abdominal pain, abdominal 
cramping, myalgia, arthralgia, malaise , tenesmus, anorexia, and headache . 
• For each day, a daily interview will be conducted by the investigator; targeted 
physical examinations will be p erformed if necessary.   
• For 8 days, 2.5 mL of venous blood into a PaxGene tube  
• For participants in the Homing Studies Subset , on day 7 post -challenge, collection 
of 15 mL of blood into serum separator tubes and 50 mL into EDTA vacutainers  
• For those not in the homing subset, on day 3 post -challenge, collection of 30 mL 
of venous blood into EDTA vacutainers  
• For those not in the homing subset, on day 7 post -challenge, collection of 15 mL 
of blood into serum separator tubes and 50 mL into EDTA vacutainers   
The management of clinical illness is described in Section 5.6. For participants that did 
not satisfy criteria for early treatment with antibiotics (Section 5. 6), antibiotic therapy will 
commence at approximately 120 hours post -challenge.  
Meanwhile, challenge par ticipants will be assigned their own bed and dresser and 
provided all their meals, including breakfast, lunch, dinner, and two snacks per day. During 
the inpatient stay, there are various forms of entertainment which can be enjoyed, 
including one large screen television and multiple smaller televisions, a pool table, board 
games, video games (Xbox and Playstation), WiFi internet  access , and two community 
computers. Laundry is provided with free, self -service washer and dryer machines. 
Participants are encouraged to bring their own reading material (books and magazines) 
and laptop computers. The only firm prohibition for materials brought with participant int o 
the inpatient unit are regarding potential weapons, tobacco, or any drugs of abuse or any 
material which could be offensive (e.g., pornographic material).  
7.6.4  Criteria for Discharge  
All four of the following criteria below must be satisfied in order to be d ischarged from the 
Research Isolation Ward:  
• two sequential Shigella  negative stool cultures, separated by 12 hours  
• absence of fever for 24 hours  
• absence of diarrhea or dysentery or other GI symptoms for 24 hours  
• completed a 3 -day course of antibiotics, per  protocol  
Subjects will receive written instructions to adhere to the following hygienic precautions 
for 4 weeks after discharge: to wash their hands with soap and water carefully and dry 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
46 them completely with a towel each time they use the bathroom, and to  avoid sharing their 
towel with others.  Subjects will also be provided a stool collection kit for bringing a stool 
sample to the scheduled clinic visit # 6. 
7.7 Visit 5 – Clinic Follow -Up, only for those not in Challenge phase 
(28 days post -2nd vaccination , ±3 days window)  
The timing of this visit is intended to be approximately Day 57 but is intended to be flexible 
because of the dependence of this visit according to the receipt of the second dose of vaccine.  
• Confirmation of ongoing consent  
• Vital signs assessment (oral temp, blood pressure, pulse)  
• Physical examination, if indicated l 
• Review for any AEs/ SAEs  and record any concomitant medications  
• For Cohorts 1 -3: 
o Collection of stool sample, at least 5 grams  
o Collection of urine sample, at least 20 mL  
o Collection of venous blood sample, 15 mL in serum separator tubes, and 90 mL 
in EDTA vacutainers  
o Provide stool collection kit  
• Provide instructions for next clinic visit  
7.8 Visit 6 – Clinic Follow -up (~7 days from discharge, +7 day 
window, only for those in th e Challenge phase)  
• Confirmation of ongoing consent  
• Collection of stool sample, at least 5 grams  
• Review for any AEs or SAEs  
• Provide stool collection kit  
• Provide instructions for next clinic visit  
7.9 Visit  7 – Clinic Follow -Up (~56 days post -2nd vaccination , ±3 
days window)  
The timing of this visit is intended to be approximately Day 85 but is intended to be flexible 
because of the dependence of this visit according to the receipt of the second dose of vaccine.  
• Confirmation of ongoing consent  
• Vital signs assess ment (oral temp, blood pressure, pulse) , if indicated  
• Physical examination, if indicated  
• Review for any SAEs  
• For Cohorts 1 -3:  
o Collection of stool sample, at least 5 grams  
o Collection of urine sample, at least 20 mL  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
47 o Collection of venous blood sample, 2.5 mL in PaxGene tube (challenge 
participants only), 15 mL in serum separator tubes , and 90 mL in EDTA 
vacutainers  
o Provide stool collection kit  
• Provide instructions for next clinic visit  
7.10 Visit 8 – Clinic Follow -Up (~16 w eeks  post -2nd vaccination , ±7 
days window)  
The timing of this visit is intended to be approximately Day 141 (or 16 -weeks after the 2nd dose of 
vaccine) but is intended to be flexible because of the dependence of this visit according to the 
receipt of the second dose of vaccine.  
• Confirmation of ongoing consent  
• Vital signs assessment (oral temp, blood pressure, pulse) , if indicated  
• Physic al examination, if indicated  
• Review for any SAEs  
• For Cohort 1 -3: 
o Collection of stool sample, at least 5 grams  
o Collection of urine sample, at least 20 mL  
o Collection of venous blood sample, 15 mL in serum separator tubes and 90 mL in 
EDTA vacutainers  
o Provide  stool collection kit  
• Provide instructions for next clinic visit  
7.11 Visit 9 – Last Follow -up (~6 months post -challenge or post -visit 
5, ±14 days window)  
The timing of this visit is intended to be approximately Day 237 (or 6 -months from visit 5 or 
challenge) b ut is intended to be flexible because of the dependence of this visit according to the 
visit 5 challenge date.  
• Vital signs assessment (oral temp, blood pressure, pulse)  
• Physical examination, if indicated  
• Review for any SAEs  
• For Cohorts 1 -3: 
o Collection of stool sample, at least 5 grams  
o Collection of urine sample, at least 20 mL  
o Collection of venous blood sample, 15 mL in serum separator tubes and 90 mL in 
EDTA vacutainers  
7.12 Unscheduled Visit(s)  or Early Termination Visits, if applicable  
Subjects  that experience any AEs, SAEs,  or experience an event of concern can be scheduled 
for an outpatient visit to be further evaluat ed. If an unscheduled visit occurs, a member of the 
clinical study team (PI, subinvestigator, nurse coordinator, or clinical nur se) will interview and 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
48 evaluate the subject to determine the cause of the visit and provide care as needed.  If an early 
termination visit were to occur, t his visit will be conduct ed as described in Section 4.4 and 
Appendix A. 
7.13 Special Consideration for COVID -19 
While there is a U.S. Public Health Emergency for COVID -19, prior to each scheduled clinic visit 
the study participants will be requested to self -report any illness symptoms prior to arrival at the 
clinic so that the study staff may discuss whether the clinic visit should be postponed or 
cancelled. These procedures should be consistent with the UMB campus research policies 
regarding COVID -19 practices.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
49 8 SAFETY ASSESSMENT AND REPORTING  
The assessment of the safety of the vaccine  will be through the detection and documentation of 
adverse effects, both solicited AEs and unsolicited AEs, and/or clinically significant laboratory 
abnormalities, from enrollment through 28 days post -vaccination . Only the occurrence of SAEs 
will be reported between Day 57  (or 28 days post -last dose of vaccine)  through the end of the 
study (Day 237) .  
8.1 Definition of Adverse Event (AE)  
An adverse event is any untoward medical occurrence in a participant after administration of the 
investigational product  and tha t does not necessarily have a causal relationship with the 
investigational product .  An AE can therefore be any unfavorable and unintended sign (including 
abnormal laboratory findings), symptoms, physical examinations, or disease temporally 
associated with  the use of the investigational product , whether or not related to the investigational 
product .  This definition includes exacerbations of pre -existing conditions.  Stable pre -existing 
conditions which do not change in nature or severity during the study a re not considered AEs; 
however these should be reported as part of the medical history.  
Solicited AEs are pre -specified AEs that could potentially be in association with the blinded study 
product . There will be no assign ing of  causality for solicited AEs to the study product  or an 
alternate etiology.  
Unsolicited AEs are any AEs reported spontaneously by the participant, observed by the study 
personnel during study visits or those identified during review of medical records or source 
document s. Investigators will attempt to assign causality of unsolicited AEs to either the study 
product  or an alternate etiology.  
8.1.1  Grading of Severity of an AE  
All AEs will be assessed by the clinician using the following guidelines to quantify severity:  
• Mild:  events require minimal or no treatment and do not interfere with the 
participant’s daily activities.  
• Moderate :  events result in a low level of inconveni ence or concern with the 
therapeutic measures. Moderate events may cause some interference with 
functioning.  
• Severe :  events interrupt a participant’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually incapacitating.  
• Life threatening :  any adverse drug experience that places the participant, in the 
view of the investigator, at immediate risk of death from the reaction as it occurred, 
i.e., it does not include a reaction that had it occurred in a more se vere form, might 
have caused death.  
AEs characterized as intermittent require documentation of onset and duration of each 
episode.  
Laboratory abnormalities will be assessed by the clinician using a protocol -defined grading 
system ( Appendix C ).   
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
50 8.1.2  Relationship to Study Product   
Relationship (causality or attribution) of all AEs to the study product  or to an alternate 
etiology (unrelated to the study) is part of the documentation process, but it is not a factor 
in determining what is (or is not) repo rted in the study.  If there is any doubt as to whether 
a clinical observation is an AE, the event should be reported.  All AEs must have their 
relationship assessed using one of two terms:  related to study product  or not related (an 
alternate etiology ca n be identified and is likely or feasible).  To help assess, the following 
guidelines are used.  
• Related to study product  (i.e., SF2a -TT15  or placebo) – There is a reasonable 
possibility (perhaps due to the timing of onset of the symptoms) that the study 
product  caused the AE. Reasonable possibility means that there is evidence to 
suggest a causal relationship between the study product  and the AE, and there is 
no reasonable alternate etiology.  
• Not Related  – The event is not related to the study product  (i.e., SF2a -TT15  or 
placebo) because of a reasonable alternate etiology.  
8.2 Definition of Serious Adverse Event (SAE)  
A serious adverse event (SAE) is any AE that results in any of the following outcomes:  
1. Death  
2. A life -threatening event. Life -threatening events mean that the study participant was, in 
the opinion of the site PI or Sponsor, at risk of death at the time of the event; it does not 
refer to an event which hypothetically might have caused death if it wer e more severe.  
3. Requires inpatient hospitalization or prolongation of existing hospitalization ; scheduled 
elective procedures will not be considered an SAE  
4. Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions  
5. Congenital abnormality or birth defect  
6. Important medical event that may not result in one of the above outcomes but may 
jeopardize the health of the study participant and/or requires medical or surgical 
intervention to prevent one of  the outcomes listed in the above definition of serious 
adverse event. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpati ent hospitalization, or the development of drug 
dependency or drug abuse.  
8.3 Reporting Procedures  
Via memory aid, s olicited reactogenicity events will be documented and reported from the time of 
study vaccination through 7 days after each dose of vaccine (Da y 8 and Day 36, respectively) . 
Post-vaccination reactogenicity will include daily: temperature; local signs (pain, redness, 
induration); and systemic symptoms (headache, fatigue, arthralgia, myalgia, diarrhea, anorexia, 
chills, and vomiting).  
Clinical safe ty laboratory AEs will be documented and reported.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
51 Unsolicited non -serious AEs will be documented and reported from the time of study vaccination 
through approximately 28 days  after vaccination.  Concomitant medications will be recorded and 
include all current medications and medications taken in the 28 days prior to enrollment and 
through 28 days after last vaccination (or early termination, if this occurs first). Concomitant 
medications include prescription and over -the-counter drugs, inclu ding herbals, vitamins, and 
supplements .  The receipt of licensed vaccines during this reporting period will also be recorded 
as a concomitant medication. The use of a new medication may prompt the evaluation of the 
occurrence of an SAE or a new diagnosis of a chronic medical condition.  
SAEs  will be documented and reported from the time of the study vaccination through end of 
study (Day 237, approximately 8 months  from enrollment) . 
8.3.1  Serious Adverse Event Detection and Reporting  
All SAEs will be:  
• recorded on a Data Collection Form  
• reported to the local IRB, per local IRB guidelines  
• reported to the Data and Safety Monitoring Board  
• reviewed and evaluated by a study clinician and the PI  
• followed through resolution by a study clinician  
All deaths and immediately life -threatening events, whether related or unrelated, will be 
reported to both the study sponsor and the DSMB within 24 hours of site awareness. Other 
SAEs regardless of relationship, will be reported to the study sponsor and the DSMB within 
72 hours of site awareness  
8.3.2  Reporting of Pregnancy  
Pregnancies occurring in study subjects will be reported on the Pregnancy Report form ; 
pregnancies will be reported to the DSMB . No further study vaccinations and/or challenges 
will be a dministered to pregnant subjects, but with the subject’s permission all protocol -
required venous blood samples will be obtained and the subject will continue to be 
followed for safety for the duration of this trial. Stool and urine specimens will continue to 
be collected, if the participant agrees.  Efforts will be made to follow all pregnancies 
reported during the course of this trial to pregnancy outcome pending the subject’s 
permission.  
 
All unexpected fatal or life -threatening suspected adverse reaction  reports will be submitted to 
the FDA within 7 days of notification from the site, in accordance with 21 CFR 312.32.  
8.4 Halting Rules  
Further enrollments , study vaccinations , and challenges  will be halted for an ad hoc DSMB  
review if any of the following even ts occur:  
• One or more participants experience a SAE , that is related to study product   
• Two or more subjects with the same severe (Grade 3 or higher) AE following 
exposure to the study product considered to be related to vaccination  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
52 The study will not continue until the DSMB  has made the determination that the halt may be lifted. 
The lifting of a halt may require changes to the protocol and/or informed consent form and is upon 
the advisement of the DSMB . 
8.5 Safety Oversight  
An independen t DSMB  will perform the oversight of safety for this study. The DSMB  will consist 
of up to 5 scientists that are not involved with the conduct of the study. The primary responsibility 
of the DSMB  is to monitor participant safety. The DSMB  considers study -specific data as well as 
relevant background information about the disease, test agent, and target population under study. 
We plan for the DSMB  to review the cumulative safety data shortly after completion of each 
inpatient phase.  The DSMB  will be empowere d to suspend the study, recommend amendments 
to the protocol, and/or to request further information for their review. One of the five scientists will 
be designated as the Independent Safety Monitor (ISM); this person is to be local to the CVD but 
not a par t of the study team. The ISM will be responsible for conducting a comprehensive review, 
should there be a halt in the study or at the request of the DSMB . Should there be a halt in the 
study, no further study product  dosing or challenges will be performed until the halt is lifted; all 
enrolled participants will continue to be followed for safety.  For participants that are in the 
Research Isolation Ward at the time of a halt, the management of diarrhea or other symptoms will 
continue, until resolution. An DSMB  Charter will be reviewed and approved by the DSMB  
members prior to the initiation of the trial and will include the scheduled frequency/timing of DSMB  
meetings, types of data for review, halting rules, and roles/responsibilities.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
53 9 CLINICAL MONITORING ST RUCTURE  
Site monitoring is conducted to ensure that the rights and well -being of human subjects are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct 
of the trial is in compliance with the currently IRB-approved protocol/amendment(s), with GCP, 
and with applicable regulatory requirement(s). Monitoring refers to the methods used by sponsors 
of investigational studies, or Contract Research Organizations (CROs) delegated site monitoring 
responsibilities, to ov ersee the conduct of, and reporting of data from, clinical investigations. Site 
monitoring includes ensuring appropriate clinical investigator supervision of study site staff and 
third party contractors.  
In order to ensure protocol compliance, monitoring v isits by a sponsor -designated professional or 
monitor will occur at scheduled intervals. The visit frequency will be defined in a monitoring plan 
(refer to Section 8.1 below) and communicated before study start to the PI and all other 
appropriate study per sonnel.  
9.1 Site Monitoring Plan  
Independent site monitoring will be conducted to assess the progress of the clinical trial and 
ensure that the rights, safety, and well -being of study participants are protected, study 
procedures, laboratory procedures, study intervention administration, and data colle ction 
processes are of high quality that comply with ICH/GCP, federal, state, and local regulatory 
authorities and that the study is conducted in accordance with the IRB -protocol and sponsor 
standard operating procedures (SOPs). Clinical monitoring of this  protocol will be performed by 
qualified individuals selected by the sponsor in accordance with ICH/GCP (Section 5.18.2) and 
as detailed in the monitoring plan.   
Site visits will be made at standard intervals as defined by the sponsor. Monitoring visits w ill 
performed in accordance with ICH/GCP (Section 5.18) and will include, but are not limited to, 
review of regulatory files, participant study charts inclusive of Data Collection Forms ( DCFs ) and 
source documents contained therein, informed consent forms,  study product accountability 
records, medical and laboratory reports, etc. Study monitors will meet with investigators to discuss 
visit findings, any problems and/or issues and actions to be taken, if any. The PI will be 
responsible for review, follow -up and resolution of monitoring findings.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
54 10 STATISTICAL CONSIDERATIONS  
10.1 Sample Size Considerations  
The sample size of the study was guided by assumptions regarding the efficacy endpoint . The 
true underlying shigellosis clinical illness attack rate , as per the BM GF CHIM working group 
endpoint definition, in the placebo group is estimated to be 60% and the vaccine efficacy is 
anticipated to be ≥50%. Sample size calculations were performed for 60% attack rates in the 
placebo group.  
In order to be able to detect a v accine efficacy of 50% with the lower b ound  of the 90% Confidence 
Interval at greater than zero with 80% power  and an attack rate of 60%  among placebo control , 
33 subjects per group (vaccinees and controls) are required. Thus, 66 subjects will be enrolled in 
the CHIM to evaluate the efficacy of SF2a -TT15. Based on the local site facilit y and staff 
resources , the 66 subjects will be split into 3 cohorts of 22 su bjects. To account for potential drop 
outs, within each cohort, 30 volunteers will be enrolled in the vaccination phase, thus a total of 90 
subjects  will be vaccinated in these three cohorts . The excess of 8 subjects per CHIM cohort is 
based on experience of CVD with previous human challenge studies. (Calculation performed by 
Chris Gast, Director of Statistics at PATH CVIA, communicated by Calman MacLennan, Senior 
Program Officer Bacterial Vaccines, Bill and Melinda Gates Foundation)  
10.2 Statistical Analysis Pl an 
Endpoints for Primary Objective . To assess the efficacy of SF2a -TT15 vaccination  against 
Moderate -Severe Shigellosis Illness ( Appendix D ), as elicited by challenge with wild -type S. 
flexneri  2a strain 2457T.  
• The point estimate of protective efficacy is to be calculated as the difference in attack 
rates among placebo recipients and vaccinees divided by the attack rate among placebo 
recipients.  The vaccine efficacy and the 90% and 95% confidence intervals will be 
calculated.   
Endpoints for Secondary Objec tive 1. To measure  the safety and clinical tolerability of two 
sequential  dose s of SF2a -TT15.  
• The number , proportion , and severity  of solicited local and systemic AEs, occurring 
within the 7 days of vaccination for each of the two doses of vaccine, among v accine 
and placebo recipients  
• The number , proportion , severity, and relatedness  of unsolicited AEs, occurring within 
28 days of vaccination for each of the two doses of vaccine, among vaccine and placebo 
recipients  
• The number , proportion , and relatedness  of SAEs, occurring at any time during the 
study, among vaccine and placebo recipients  
Endpoints for Secondary Objective  2. To evaluate performance of efficacy of SF2a -TT15 
vaccination against different case definitions and endpoint definitions ( Appendix D ), as elicited 
by challenge with wild -type S. flexneri  2a strain 2457T.  
• Vaccine e fficacy for the prevention of any diarrhea , dysentery, fever , or any combination 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
55 of the three criteria (diarrhea, dysentery, and/or fever)  
• Vaccine efficacy for the p revention of Severe Shigellosis (according to the CVD 
Historical Definition)  
• The mean and median duration of diarrhe a, dysentery, and fever , among vaccine and 
placebo recipients  
• The median and mean number of loose stools (grade 3 or higher), duration of l oose 
stools (grade 3 or higher), cumulative volume of loose stools (grade 3 or higher), 
maximum 24 -hour loose stool output, among vaccine and placebo recipients  
• The median and mean time to onset and duration of diarrhea, dysentery, or fever  
• The number and proportion of fevers, participants requiring early initiation of antibiotics 
or intravenous fluids, and participants with vomiting.  
• A Shigella  Disease Severity Score will be calculated for each challenge subject.   
Endpoints for Secondary Objective  3. To evaluate the efficacy of SF2a -TT15 vaccination 
against any positive (qualitative) or quantitative fecal shedding of wild -type S. flexneri  2a.  
• The geometric mean number (and interquartile range)  of the daily and peak quantitative 
counts (cf u/gram stool) , among vaccine and placebo recipients  
• The mean and median numbers of days of shedding  of the challenge strain  
• The area -under -the-curve (AUC), as calculated using the trapezoidal rule, for each 
challenged participant  
Endpoint s for Secondary Objective 4 . To measure the serum IgG immune responses to SF2a 
LPS following vaccination and challenge . 
• The number and proportion of responders (4 -fold increases over baseline) in serum anti-
S. flexneri  2a LPS IgG ELISA antibody  
• The geometri c mean titer (GMT), mean fold -rises (compared to baseline), and peak -
post-vaccination and post -challenge serum anti-S. flexneri  2a LPS IgG ELISA antibody  
Endpoint s for Secondary Objective 5. To measure the bactericidal activity of SF2a -specific IgG 
followi ng vaccination and challenge.  
• The number and proportion of responders (4 -fold increases over baseline) in serum 
bactericidal activity (SBA) antibody  
• The geometric mean titer (GMT), mean fold -rises (compared to baseline), and peak -
post-vaccination and post -challenge SBA antibody  
Endpoint s for Secondary Objective 6. To measure the IgA and IgG ASC and ALS immune 
responses to SF2a LPS following vaccination and challenge.   
• The number  and proportion of responders (≥8 SFC) of anti -S. flexneri 2a LPS IgG and 
IgA ASC  
• The GMT, mean fold -rises (compared to baseline), and peak post -vaccination and post -
challenge anti-S. flexneri 2a LPS IgG and IgA ASC  
• The number and proportion of responders (≥4 -fold increases over baseline) of anti -S. 
flexneri 2a LPS IgG and IgA ALS  
• The GMT, mean fold -rises (compared to baseline), and peak post -vaccination and post -
challenge anti-S. flexneri 2a LPS IgG and IgA ALS  
For the  endpoints for primary and secondary objectives, t he distributions of all measures will be 
examined and described in terms of sample sizes, means, standard deviations, median s, 
interquartile ranges, minima and maxima for continuous variables (such as durat ion of diarrhea, 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
56 dysentery, and fever , Shigella  Disease Severity Score, and geometric mean titers); and counts 
and proportions for categorical variables (such as the defined endpoints for efficacy [Y/N]), for 
each group separately.  Continuous variables of interest that are not normally distributed will be 
transformed if needed. To compare the vaccine group with the placebo group, t test or Mann -
Whitney U test will be used for continuous variables as appropriate; and Chi -squared test  or 
Fisher’s exact will be used for categorical variables as appropriate. All analyses will be performed 
using Stata/SE version 15.  
Exploratory Objective s: 
1.  To measure pro -inflammatory cytokine markers in stool following challenge . 
2. To measure IgG su bclasses (IgG1 and IgG2) to SF2a LPS following vaccination and 
challenge.  
3.  To measure serum IgA immune responses to SF2a LPS following vaccination and 
challenge . 
4.  To measure urinary secretory IgA to SF2a LPS following vaccination and challenge and to  
store urine samples for potential later analysis of anti -SF2a LPS IgG  
5.  To measure the IgA and IgG ASC expressing mucosal homing markers (e.g., integrin α4β7 -
positive) to SF2a LPS following vaccination and challenge  
6.  To explore the correlates of immunity with protection  
7.  To compare the immunologic assays performed by different research laboratories  
8.  To collect, separate and store (at -70° C or colder) PBMC so that in future studies the 
immune responses to SF2a -TT15 can be furth er characterized in great detail, including the 
measurement of T memory and effector cells, B memory cells, homing markers and cytokine 
production  
9.  To collect and store serum, urine, and stool specimens for future studies, including but not 
limited to antibody microarray analysis, fecal 16S rRNA microbiome, transcriptomics, and 
proteomics.  
The general approach to the analysis of serum immunogenicity data (such as IgA and IgG 
subclasses) will be to calculate the number and proportion of responders (4 -fold increases over 
baseline), the GMT, mean fold -rises (compared to baseline), and peak  values post-vaccination 
and post -challenge . The comparison of the different research laboratories (e.g., TAU and 
WRAIR ELISA assay data) will be to calculate a rank correlation or compare the percentile rank 
using sign test.  Comparisons in the measures of immunogenicity will be made to the clinical 
outcomes (endpoints) data to generate potential correlations of protection.  
10.3 General Statistical Principles  
All participa nts in the enrolled population who are randomized and receive a masked vaccination 
will be included in the Full Analysis (FA) Safety Population  (n=90) . All safety analysis will be 
performed using this FA safety population. Treatment groups for the safety a nalysis will be 
assigned according to the actual treatment received at enrollment. All participants that complete 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
57 the inpatient challenge will be included in the Full Analysis (FA) Efficacy Population  (n=66).  All 
efficacy and shedding analysis will be per formed using this FA efficacy population.  
All participants in the FA safety population that received two doses of blinded study product and 
have no major protocol violations that are determined to potentially interfere with the 
immunogenicity assessment of  the vaccine and who have at least one post-second vaccination 
immunogenicity assessment will be included in the Per Protocol (PP) Immunogeni city Population.  
The PP immunogenicity population will serve as the primary analysis population for the 
immunogeni city endpoints. The criteria for exclusion of participants from the PP population will be 
established before breaking the blind and will be based on the blinded review of protocol 
deviation s. 
In general, all missing data will be treated as missing complete ly at random and no imputation will 
be performed except for the safety endpoints, as described below. If some safety data are 
available for a participant in the FA safety population, but respective secondary endpoint related 
data are missing, then the part icipant will be included in the safety analysis and data will be treated 
as follows for immediate AEs, unsolicited AEs and SAEs.  
• If Severity is missing for any AE, then it will be considered as an AE of maximum severity 
(Grade 3) "Severe", unless it is cap tured as SAE.  
• If "Relationship" is missing, then it will be considered as "Related" to the vaccine 
administered.  
• If, for Start date, the day of event/condition is missing due to any AE, then it will be imputed 
as the date of last visit.  
• If the Stop date of  an AE is missing, then it will be treated as ongoing.  
For solicited AEs, the following assumptions will be made:  
• If dates are missing, but symptoms are reported, then the day post vaccination will be 
used to calculate the date of the symptom.  
• If a symptom  is not reported at any time through Day 7, then no imputation for missing 
data will be performed. The data will be summarized as not reported on the tables.  
 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
58 11 QUALITY CONTROL AND QUALITY ASSURANCE  
All clinical trials conducted by the University of Maryland Center for Vaccine Development (CVD) 
are internally audited for quality assurance (QA) quality control (QC) under the CVD -Wide Quality 
Management Plan (QMP).  The purpose of the QMP is to describe  QA/QC procedures designed 
to ensure site and investigator compliance with applicable regulations, adherence to the IRB -
approved protocol, generation of credible, quality data, protect data integrity, and safeguard the 
safety and well -being of study partic ipants. The plan has the authority to enforce and correct 
clinical and laboratory deficiencies observed during the conduct of a trial/research study.   
Quality Management (QM) activities will proceed in compliance with E6(R2) Good Clinical 
Practice:  Integ rated Addendum to ICH E6(R1), March, 2018.  Consistent with the University of 
Maryland Center for Vaccine Development site -wide QMP, a Protocol -specific QMP (Appendix B  
of the site -wide QMP ) will be developed for this protocol.  The Protocol -specific plan applies a 
risk-based approach to QM focused on the essential elements of clinical trial conduct, i.e., 
recruitment strategies, the informed consent process, eligibility, study -related procedures, clinical 
and safety assessments, AEs/ SAEs, study product management, specimen management, and 
data management.  The plan will also outline site delegation of QC/QA responsibilities, frequency 
of regulatory file reviews, the audit schedule (e.g., sample size, audit frequency, critical data tha t 
will be reviewed, communication, etc.), documentation and reporting of QA findings /queries , and 
the development of corrective action preventive action (CAPA) plans (as indicated).  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
59 12 ETHICS/PROTECTION OF HUMAN SUBJECTS  
12.1 Ethical Standard  
The investigator will  ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the US National Commission for the Protection of Human Subjec ts of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the 
ICH E6; 62 Federal Regulations 25691 (1997).  
12.2 Institutional Review Board  
The local institution must provide for the review and approval of this protocol and the associated 
informed consent documents by an appropriate ethics review committee or IRB. Any amendments 
to the protocol or consent materials must also be approved before they are placed into use unless 
it is in the best interest of the subjects’ safety to implement changes prior to approval. In both the 
United States and in other countries, only institutions holding a current U. S. Federal -Wide 
Assurance issued by the Office for Human Research Protections (OHRP) may participate.  
Refer to: http://www.hhs.gov/ohrp/assurances/     
Prior to enrollment of subjects into this clinical study, the protocol and the informed consent 
form(s) will be reviewed and approved by the appr opriate IRB. Any amendments to the protocol 
or consent materials will also be reviewed and approved by the appropriate IRB. The responsible 
official for the IRB will sign the IRB letter of approval of the protocol prior to the start of this clinical 
study.  Should amendments to the protocol be required, the amendments will be submitted to the 
IRB; an IRB letter of approval of the amendment must be obtained prior to acting upon the 
amendment in the protocol.  
The contact information for the local IRB and the Human Research Protections Office ( HRPO ) is: 
University of Maryland , Baltimore  
Human Research Protections Office  
620 W. Lexington Street, Second Floor  
Baltimore, MD 21201 , U.S.A.  
Phone 1 -410-706-5037  
12.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual’s agree ment  to participate in 
the study and continues throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of this therapy will be provided to the participan t.  Consent forms 
describing in detail the study, procedures , and risks associated are given to the potential 
participant and written documentation of informed consent is required prior to starting any study 
procedure.  Consent forms will be IRB -approved a nd the participant will be asked to read and 
review the document. Upon reviewing the document, the investigator will explain the research 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
60 study to the participant and answer any questions that may arise.  The participants will sign the 
informed consent doc ument prior to any procedures being done specifically for the study.  The 
participant should have the opportunity to discuss the study with their surrogates or think about it 
prior to agreeing to participate.  The participant may withdraw consent at any ti me throughout the 
course of the trial.  A copy of the informed consent document will be given to the participant for 
their records.  The rights and welfare of the participant will be protected by emphasizing to them 
that the quality of their medical care w ill not be adversely affected if they decline to participate in 
this study.  
12.4 Exclusion of Women, Minorities, and Children (Special 
Populations)  
This clinical study will include women, children of 18 years of age and older, and all minorities 
who meet the inclusion/exclusion criteria, regardless of religion, sex, or ethnic background.  
12.5 Subject Compensation  
Thoughtful consideration has been made toward s ubject compensation for healthy volunteer 
participants enrolled into clinical studies involving non -license d vaccines and experimental 
infections. The overarching ethical issues which the CVD’s compensation scheme attempts to 
address are: (1) avoidance of “undue inducement”, (2) payments which may result in economically 
disadvantaged populations bearing an over whelming share of the risks and burdens of research, 
and (3) payments which may violate the ethical norms of the investigator -subject relationship by 
turning it into a commercial relationship.  The compensation scheme for this study is adopted from 
the Wage -Payment Model.52 Unde r the Wage -Payment Model, a participant is assumed to require 
little skill, but does require time, effort, and an expectation of experiencing u ndesirable or 
uncomfortable procedures.  Therefore, the CVD’s compensation rates are calculated to 
approximate th e hourly wages of an unskilled high -risk laborer. The compensation rate used in 
this study is an standard rate that is used across all of CVD’s clinical research. This compensation 
rate is clearly described in the informed consent form and is unlikely to b e unduly coercive.  
12.6 Subject Confidentiality  
Subject (participant) confidentiality is strictly held in trust by the investigators, their staff, and the 
Sponsor.  This confidentiality is extended to cover testing of biological samples and other testing 
in addition to the clinical information relating to participant.  
The study protocol, documentation, data, and all other information generated will be held in strict 
confidence.  No information concerning the study , or the data , will be released to any unautho rized 
third party without prior written approval of the sponsor.  
The study monitor , or other authorized representatives of the sponsor , may inspect all documents 
and records required to be maintained by the investigator including , but not limited to, medic al 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
61 records (office, clinic, or hospital) and pharmacy records for the participants in this study.  The 
clinical study site will permit access to such records.  
Participant identity data will be contained in paper study records which will be kept in a locked  file 
cabinet and in a secure electronic database, accessible only to authorized users at each clinical 
site. The study database will be user -restricted and password -protected. The study database will 
identify participants by a coded study Volunteer ID num ber assigned by clinical site personnel, 
thus participants will not be identified by name.  
Subject confidentiality and the limits for access to records is described in the informed consent 
form.  
12.7 Future Use of Stored Specimens  
It is intended that any remain ing specimens at the closure of the study will be stored at the CVD 
or partners (i.e., WRAIR, Institut Pasteur, or Tel Aviv University) and may be used for further 
immunological analyses . Samples that are sent to Institut Pasteur may be stored for up to 15  
years. All other samples may be stored indefinitely. Participants may choose to have their 
specimens destroyed and must do this in a written request. This is described in the consent form.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
62 13 ACCESS TO SOURCE DATA/DOCUMENTS  
Source data includes  all informat ion, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for validation of the clinical data.  Examples of these original 
documents and data records include, but are not limited to, hospital records, clini cal and office 
charts, laboratory notes, memoranda, subjects’ memory aid or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions certified 
after verification as being accurate and complete, microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, and subject files and records kept at the pharmacy, at the laboratories, 
and medico -technical departments involved in the clinical trial.  All information on the DCFs  will 
be traceab le to these source documents, which are maintained in the subject’s study file.   
The PI is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the 
data reported. Source documents are maintained for recording data for each su bject enrolled in 
this clinical study. Study subjects’ data collected on the DCF during the trial will only be identified 
by subject number.  If, as an exception, it is necessary for safety or regulatory reasons to identify 
the patient, both the Sponsor an d the Investigator are bound to keep this information confidential.  
All the information required by the protocol should be provided; any omissions require 
explanation.  Source document s and DC Fs should be completed and available for monitoring 
and/or collection within a timely manner so that the monitor may check the entries for 
completeness, accuracy and legibility, and ensure that the DCFs  are signed by the Investigator, 
and ready for transmi ssion to the Sponsor.  
All source documents and DCFs  should be completed in a neat, legible manner to ensure 
accurate interpretation of data. Black or blue ink is required to ensure clarity of reproduced copies. 
When making a change or correction, cross out t he original entry with a single line and initial and 
date the change. DO NOT ERASE, OVERWRITE OR USE CORRECTION FLUID OR TAPE ON 
THE ORIGINAL.  
The Investigator or designee must enter the information required by the protocol onto the DCF 
provided.  The Spo nsor’s clinical site monitor will review the DCF for completeness and accuracy 
and instruct site personnel to make any required corrections or additions.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
63 14 DATA HANDLING AND RECORD KEEPING  
The site PI is responsible for ensuring the  accuracy, completeness, l egibility, and timeliness of 
the data reported.  
Source data will be generated by the site and collected on d ata collection forms .  Source data will 
be entered into a REDCap data management system, managed by the Clinical and Translational 
Research Informat ics Center (CTRIC), University of Maryland School of Medicine. REDCap is a 
secure web -based application for building an electronic database that provides a 21 CFR Part 11, 
FISMA, and HIPAA -compliant environment. Quality control audits of all key safety, la boratory, 
and clinical data in the database will be made after data entry has been completed.  Coexistent 
medical conditions, AEs and other medical events will be coded using MedDRA dictionary. 
Concomitant medications will be coded using WHO -DD dictionary.  When the database has been 
declared to be complete and accurate, the database will be locked.  Any changes to the database 
after that time will only be by joint written agreement of the study team.   
Data reported in  REDCap  are derived from the data collec tion forms and should be consistent 
with the data collection forms or the discrepancies should be explained.  
The sponsor and/or its designee will provide guidance to the site PIs and other study personnel 
on making corrections to the data collection forms.  
As part of the development program for the Shigella  vaccine candidate, unblinded coded data 
(including treatment assignment ; unblinded safety, immunogenicity, and challenge results data ; 
and unblinded reports for the DSMB) collected from this clinical trial will be shared between 
unblinded teams of the sponsor and the vaccine developer.  
After  the adjudication of the challenge phase results, the vaccine developer (Institut Pasteur)  will 
be unblinded. Up to three members of Institut Pasteur will have access to the unblinded data for 
the purpose  of in-depth analysis of the immunogenicity data  and challenge outcomes overall, 
per cohort,  and per volunteer.  Considering  the global  need  for a Shigella vaccine,  rapid  
assessment  of the potential efficacy of the vaccine  candidate is required  to move  the vaccine 
approach forward.  
At Institut  Pasteur,  all data  will be stored  on a secure  server  accessible  with a login  and password 
to which  only the unblinded  persons  have  access. The  risk of impact  on the study  is minimized  
as the Institut Pasteur personnel is not involved in the clinical evaluation and management of the 
participants.  Furthermore,  unblinding  of Institut  Pasteur  staff will occur  during  the follow  up phase 
of the trial, the treatments  and challenges  have  already  been  completed.  Guidelines  for 
information sharing with blinded project team members, particularly at the sponsor and the 
laboratories performing the safety and immunogenicity analyses, are in place at Institut Pasteur.  
The data will be shared  with the Bill & Melinda  Gates  Foundation  and the Gates  Medical  Research 
Institute  as they are partners  of the Institut  Pasteur  Shigella  vaccine  candidate  development.  
These data may comprise aggregated data but also per subject analyses. Subject codes will not 
be included in shared data, so that th e blinding of the treatment of the individual subjects will be 
maintained. Aggregated data might also be shared with the sponsor.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
64  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
65 15 IN SUMMARY, EXCEPT THE PHARMACIST AND THE 
UNBLINDED STATISTICIAN AT THE SPONSOR, NONE 
OF THE INDIVIDUALS INVOLVED IN THE STUDY 
(PARTICIPANTS, CLINICAL AND LABORATORY STAFF, 
SPONSOR PERSONNEL) WILL HAVE ACCESS TO 
TREATMENT ASSIGNMENT. DATA WILL BE UNBLINDED  
AFTER ALL SUBJECTS WILL HAVE COMPLETED THE 
STUDY AND THE DATABASE LOCK WAS COMPLETED 
OR IN CASE OF EMERGENCY. PERSONNEL AT THE 
VACCINE DEVELOPER WHO ARE NOT INVOLVED IN 
STUDY CONDUCT WILL BE UNBLINDED AFTER THE 
ADJUDICATION FOR DECISION MAKING FOR 
PROGRES SION OF THE SHIGELLA VACCINE 
DEVELOPMENT.  PUBLICATION POLICY  
All investigators funded by the Bill & Melinda Gates Foundation must agree to their Open 
Access Policy. https://www.gatesfoundation.org/How -We-Work/General -Information/Open -
Access -Policy   
The Foundation’s Open Access Policy contains the following elements:  
1. Publications Are Discoverable and Accessible Online.  Publicat ions will be deposited in a 
specified repository(s) with proper tagging of metadata.  
2. Publication Will Be On “Open Access” Terms.  All publications shall be published under 
the Creative Commons Att ribution 4.0 Generic License  (CC BY 4.0) or an equivalent 
license. This will permit all users of the publication to copy and redistribute the material in 
any medium or format and transform and build upon the material, inc luding for any purpose 
(including commercial) without further permission or fees being required.  
3. Foundation Will Pay Necessary Fees.  The Foundation w ill pay reasonable fees required 
by a publisher to effect publication on these terms.  
4. Publications Will Be Accessible and Open Immediately.  All publications shall be available 
immediately upon their publication, without any embargo period.    
5. Data Underlying Published Research Results Will Be Accessible and Open Immediately.  
The Foundation will require tha t data underlying the published research results be 
immediately accessible and open.   
Therefore, f ollowing completion of this clinical trial, the investigator s intend to  publish the results 
of this research in a peer-reviewed scientific journal , within 12 months of locking the database . 
The International  Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a trials -registration policy as a condition for publication.  This policy requires that all clinical trials 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
66 be registered i n a public trials registry, such as ClinicalTrials.gov*  (http://clinicaltrials.gov/ ), which 
is sponsored by the National Library of Medicine.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
67 16 LITERATURE REFERENCES  
1. Kotloff KL, Pasetti MF, Shirley D -A, et al. Phase 1 and 2 Trials of CVD 1208S, a live, oral 
DguaBA,Dsen,Dset Shigella flexneri 2a vaccine. Oral Abstract presentation, Vaccines for Enteric 
Diseases; 2013; Bangkok, Thailand.  
2. Kotloff K L, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for 
vaccine development and implementation of control strategies. Bull World Health Organ. 
1999;77(8):651 -666. 
3. Khalil IA, Troeger C, Blacker BF, et al. Morbidity and m ortality due to shigella and enterotoxigenic 
Escherichia coli diarrhoea: the Global Burden of Disease Study 1990 -2016. Lancet Infect Dis. 
2018;18(11):1229 -1240.  
4. Livio S, Strockbine NA, Panchalingam S, et al. Shigella isolates from the global enteric 
multicenter study inform vaccine development. Clin Infect Dis. 2014;59(7):933 -941. 
5. Liu J, Platts -Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify 
causes of diarrhoea in children: a reanalysis of the GEMS case -control st udy. Lancet. 
2016;388(10051):1291 -1301.  
6. Haley CC, Ong KL, Hedberg K, et al. Risk factors for sporadic shigellosis, FoodNet 2005. 
Foodborne Pathog Dis. 2010;7(7):741 -747. 
7. Arvelo W, Hinkle CJ, Nguyen TA, et al. Transmission risk factors and treatment o f pediatric 
shigellosis during a large daycare center -associated outbreak of multidrug resistant Shigella 
sonnei: implications for the management of shigellosis outbreaks among children. Pediatr Infect 
Dis J. 2009;28(11):976 -980. 
8. Kasper MR, Lescano AG, Lucas C, et al. Diarrhea outbreak during U.S. military training in El 
Salvador. PLoS One. 2012;7(7):e40404.  
9. Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers' diarrhea. J Travel Med. 
2001;8(Suppl 2):S26 -30. 
10. Marcoleta A, Toro C, Prado V, e t al. [Antibiotic susceptibility patterns among Shigella sonnei, 
isolated during three different periods in Region Metropolitana, Chile]. Rev Chilena Infectol. 
2013;30(6):616 -621. 
11. DuPont HL, Hornick RB, Dawkins AT, Snyder MJ, Formal SB. The response of  man to virulent 
Shigella flexneri 2a. J Infect Dis. 1969;119(3):296 -299. 
12. Levine MM, DuPont HL, Formal SB, et al. Pathogenesis of Shigella dysenteriae 1 (Shiga) 
dysentery. J Infect Dis. 1973;127(3):261 -270. 
13. Taylor DN, Echeverria P, Pal T, et al. The role of Shigella spp., enteroinvasive Escherichia coli, 
and other enteropathogens as causes of childhood dysentery in Thailand. J Infect Dis. 
1986;153(6):1132 -1138.  
14. Herrington DA, Van de Verg L, Formal SB, et al. Studies in volunteers to evaluate candidate 
Shigella vaccines: further experience with a bivalent Salmonella typhi -Shigella sonnei vaccine 
and protection conferred by previous Shigella sonnei disease. Vaccine. 1990;8(4):353 -357. 
15. Kotloff KL, Nataro JP, Losonsky GA, et al. A modified Shigella volunteer challenge model in 
which the inoculum is administered with bicarbonate buffer: clinical experience and implications 
for Shigella infectivity. Vaccine. 1995;13(16):1488 -1494.  
16. Ferreccio C, Prado V, Oj eda A, et al. Epidemiologic patterns of acute diarrhea and endemic 
Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol. 
1991;134(6):614 -627. 
17. Levine MM, Gangarosa EJ, Werner M, Morris GK. Shigellosis in custodi al institutions. 3. 
Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated 
shigella vaccines. J Pediatr. 1974;84(6):803 -806. 
18. Ashkenazi S, Dinari G, Zevulunov A, Nitzan M. Convulsions in childhood shigellosis. Cl inical and 
laboratory features in 153 children. Am J Dis Child. 1987;141(2):208 -210. 
19. Koster F, Levin J, Walker L, et al. Hemolytic -uremic syndrome after shigellosis. Relation to 
endotoxemia and circulating immune complexes. N Engl J Med. 1978;298(17):9 27-933. 
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
68 20. Huskins WC, Griffiths JK, Faruque AS, Bennish ML. Shigellosis in neonates and young infants. J 
Pediatr. 1994;125(1):14 -22. 
21. Altman RL, Li KI, Juster F, Van Horn KG, Schlesinger I, Hetzler T. Hip joint infection caused by 
Shigella sonnei in a  one-year-old boy. Pediatr Infect Dis J. 1994;13(12):1156 -1158.  
22. Squires RH, Keating JP, Rosenblum JL, Askin F, Ternberg JL. Splenic abscess and hepatic 
dysfunction caused by Shigella flexneri. J Pediatr. 1981;98(3):429 -430. 
23. Rubin HM, Eardley W, Nic hols BL. Shigella sonnei osteomyelitis and sickle -cell anemia. Am J Dis 
Child. 1968;116(1):83 -87. 
24. Black RE, Brown KH, Becker S, Alim AR, Huq I. Longitudinal studies of infectious diseases and 
physical growth of children in rural Bangladesh. II. Inciden ce of diarrhea and association with 
known pathogens. Am J Epidemiol. 1982;115(3):315 -324. 
25. Sieper J, Braun J, Wu P, Hauer R, Laitko S. The possible role of Shigella in sporadic enteric 
reactive arthritis. Br J Rheumatol. 1993;32(7):582 -585. 
26. Finch M,  Rodey G, Lawrence D, Blake P. Epidemic Reiter's syndrome following an outbreak of 
shigellosis. Eur J Epidemiol. 1986;2(1):26 -30. 
27. Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med. 
1983;309(26):1606 -1615.  
28. Reveille JD, Hi rsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA -B27 in the 
US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum. 
2012;64(5):1407 -1411.  
29. Cohen D, Green MS, Block C, Slepon R, Lerman Y. Natural immunity to shigellosis in two groups 
with different previous risks of exposure to Shigella is only partly expressed by serum antibodies 
to lipopolysaccharide. J Infect Dis. 1992;165(4):785 -787. 
30. Black RE, Levine MM, Clements ML, et al. Prevention of shigellosis by a Salmonella typhi -
Shigella sonnei bivalent vaccine. J Infect Dis. 1987;155(6):1260 -1265.  
31. Oaks EV, Hale TL, Formal SB. Serum immune response to Shigella protein antigens in rhesus 
monkeys and humans infected with Shigella spp. Infect Immun. 1986;53(1):57 -63. 
32. Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM. Progress and pitfalls in 
Shigella vaccine research. Nat Rev Gastroenterol Hepatol. 2013;10(4):245 -255. 
33. Kotloff KL, Simon JK, Pasetti MF, et al. Safety and immunogenicity of CVD 1208S, a live, oral 
DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal -free media. Hum 
Vaccin. 2007;3(6):268 -275. 
34. Venkatesan MM, Ranallo RT. Live -attenuated S higella vaccines. Expert Rev Vaccines. 
2006;5(5):669 -686. 
35. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to 
confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 
1995;171( 6):1387 -1398.  
36. Cohen D, Atsmon J, Artaud C, Meron -Sudai S, Gougeon ML, Bialik A. A phase I dose escalation 
study to assess the safety and immunogenicity of the SF2a -TT15 conjugate vaccine against S. 
flexneri  2a in healthy adult volunteers (Preliminary R esults). Vaccines for Enteric Diseases; 9 -11 
October 2017, 2017; Sao Rafael Atlantico Hotel, Albufeira, Portugal.  
37. Cohen D, Ashkenazi S, Green MS, et al. Double -blind vaccine -controlled randomised efficacy trial 
of an investigational Shigella sonnei con jugate vaccine in young adults. Lancet. 
1997;349(9046):155 -159. 
38. Passwell JH, Ashkenzi S, Banet -Levi Y, et al. Age-related efficacy of Shigella O -specific 
polysaccharide conjugates in 1 -4-year-old Israeli children. Vaccine. 2010;28(10):2231 -2235.  
39. Walker RI. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for 
infants and children. Vaccine. 2015;33(8):954 -965. 
40. Walker RI, Wierzba TF, Mani S, Bourgeois AL. Vaccines against Shigella and enterotoxigenic 
Escherichia col i: A summary of the 2016 VASE Conference. Vaccine. 2017;35(49 Pt A):6775 -
6782.  
41. Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 
2016;34(26):2887 -2894.  
Protocol Shigella CVD 3000 0 Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
69 42. Bohles N, Bohles N, Busch K, Busch K, Hensel M, He nsel M. Vaccines against human diarrheal 
pathogens: current status and perspectives. Hum Vaccin Immunother. 2014;10(6):1522 -1535.  
43. Kim YJ, Yeo SG, Park JH, Ko HJ. Shigella vaccine development: prospective animal models and 
current status. Curr Pharm Bio technol. 2013;14(10):903 -912. 
44. Porter CK, Lynen A, Riddle MS, et al. Clinical endpoints in the controlled human challenge model 
for Shigella: A call for standardization and the development of a disease severity score. PLoS 
One. 2018;13(3):e0194325.  
45. Riddle MS, Kaminski RW, Di Paolo C, et al. Safety and Immunogenicity of a Candidate 
Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single -Blind, 
Randomized Phase I Study. Clin Vaccine Immunol. 2016;23(12):908 -917. 
46. Kotloff KL, Pasetti MF, Barry EM, et al. Deletion in the Shigella enterotoxin genes further 
attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and 
CVD 1208. J Infect Dis. 2004;190(10):1745 -1754.  
47. Cohen D, Block C, Green MS, Lowell G, Ofek I. Immunoglobulin M, A, and G antibody response 
to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J Clin 
Microbiol. 1989;27(1):162 -167. 
48. Cohen D, Orr N, Robin G, et al. Detect ion of antibodies to Shigella lipopolysaccharide in urine 
after natural Shigella infection or vaccination. Clin Diagn Lab Immunol. 1996;3(4):451 -455. 
49. Shimanovich AA, Buskirk AD, Heine SJ, et al. Functional and Antigen -Specific Serum Antibody 
Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. 
Clin Vaccine Immunol. 2017;24(2).  
50. El-Kamary SS, Cohen MB, Bourgeois AL, et al. Safety and immunogenicity of a single oral dose 
of recombinant double mutant heat -labile toxin derived from enterotoxigenic Escherichia coli. Clin 
Vaccine Immunol. 2013;20(11):1764 -1770.  
51. Toapanta FR, Simon JK, Barry EM, et al. Gut -Homing Conventional Plasmablasts and CD27( -) 
Plasmablasts Elicited after a Short Time of Exposure to an Oral L ive-Attenuated Shigella Vaccine 
Candidate in Humans. Front Immunol. 2014;5:374.  
52. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research 
participation. N Engl J Med. 1999;341(3):198 -203. 
 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
70 APPENDIX A 1: SCHEDULE OF EVENTS , CHALLENGE S UBJECTS (COHORTS 1 -3) 
 
CHALLENGE   (n=66)       admit          discharge      
Study Day  Sc 1 8 29 36a 55a 56a 57a 58a 59a 60a 61a 62a 63a 64a 65a 66a 69a  85a  141a  237b  
Consent, Review Eligibility  x                                       
Screening/Safety Clinical Labs  25 mL        10 mL                               
Screening Stool Culture‡        x                               
urine pregnancy, prior vaccine/challenge    x   x       x                         
Vaccination    #1   #2                                 
Challenge (3-days Antibiotics)                C         A A A          
Memory Aid, distribute & collect    d c d c                               
Adverse Events *  x x x x x x x x x x x x x x x x x x x x 
Stool Cultures               x# x x x x x x x x x x x** x**   x** 
                                 
1) Serum: ELISA antibody, SBA, subclasses    15 15 15 15   15#               15     15 15 15 
2a) Fresh PBMC: ASC & ALS (all 22 vols/cohort)    20 20 20 20   20#               20           
2b) Fresh PBMC: ASC & ALS Homing Subset ( up to 8 /cohort)†     30   30                   30           
3a) cryopreserve PBMC: Teff/Tm cells, memory B  (all 22)    90   90     90#                     90 90 90 
3b) cryopreserve PBMC: pTfh ( not in Homing)†                     30       30           
4) Stool: IgA ELISA    x   x     x#                     x x x 
5) urine: for sIgA/IgG (Dani Cohen analysis)   x  x     x#                x    x x x 
6) whole blood (PaxGene) for transcriptomics                2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5     2.5   
                      
serum banking for microarray    x x x x   x#               x     x x x 
stool (no preservative) for cytokine analysis         x x x x x x x x       
stool banking (RNALater) for microbiome,  transcriptomics, etc.   x   x     x# x x x x x x x x x x  x x x 
 
‡  instead of stool culture, it is acceptable to use BioFire GI Panel (or equivalent molecular diagnostic test)  
*  Unsolicited AEs will be reported from enrollment through 28 days after each dose of vaccine, SAEs will be reported from en rollm ent through study completion (i.e., Day 1 through Day 237)  
** Only qualitative stool cultures will be performed on Days 69, 85 and 237 (only on participants that were challenged)  
†  Up to eight volunteers per cohort (i.e., up to twenty -four total) will be randomly selected to participate in the “Homing Studies Subset” and will be requested to provide an additional volume 
of blood for homing studies (i.e., Days 8, 36, and 64); these volunteers will also be preferentially selected to participate in the challe nge phase of the study. On challenge days, only a 
maximum of six volunteers will contribute to the homing study (Day 64). Challenge participants not in the Homing Studies Subs et will provide blood 3 days and 7 days post -challenge (i.e., 
Days 60 and 64) for  peripheral T follicular helper cell (pTfh) studies.  
#  These indicated research blood, stool, and urine specimens may be collected at any point prior to challenge, during acclimati zation (i.e., Days 55, 56, or 57)  
Note: Some specified visit days (and wind ows) are  intended to be relative to timing of 2nd vaccination (a) or challenge (b) 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
71 APPENDIX A2: SCHEDULE OF EVENTS, VACCINE -ONLY SUBJECTS (COHORTS 1 -3) 
VACCINATION only   (n=24)                   
Study Day  Sc 1 8 29 36a   57a         85a  141a 237a  
Consent, Review Eligibility  x                          
Screening/Safety Clinical Labs  x       10 mL                   
Screening Stool Culture‡        x                   
urine pregnancy, prior vaccine/challenge    X   x                    
Vaccination    #1   #2                    
Memory Aid, distribute & collect    d c d c                  
Adverse Events *   X x  x x   x         x x x 
                     
1) Serum: ELISA antibody, SBA, subclasses    15 15 15 15   15         15 15 15 
2a) Fresh PBMC: ASC & ALS (all 22 vols/cohort)    20 20 20 20                  
2b) Fresh PBMC: ASC & ALS Homing Subset ( up to 8 /cohort)†     30   30                   
3a) cryopreserve PBMC: Teff/Tm cells, memory B    90   90     90         90 90 90 
4) Stool: IgA ELISA    X   x     x         x x x 
5) urine: for sIgA/IgG (Dani Cohen analysis)    X   x     x         x x x 
                    
serum banking for microarray    X x x x   x         x x x 
stool banking (RNALater) for microbiome, etc.    X   x     x            
 
‡  instead of stool culture, it is acceptable to use BioFire GI Panel (or equivalent molecular diagnostic test)  
*  Unsolicited AEs will be reported from enrollment through 28 days after each dose of vaccine ; SAEs  will be reported from enrollment  through study completion (i.e., 
Day 1 through Day 237)  
†  It is intended that the up to eight  volunteers per cohort (i.e., up to twenty -four total) which are randomly selected to participate in the “Homing Studies Subset” will 
be preferentially selected to participate in the challenge phase of the study. Nonetheless the volunteer cannot be compell ed to participate in the challenge phase 
and therefore there is no Day 64 blood draw for homing studies if they do not participate in the challenge phase.   
Note: Some specified visit days (and windows) are intended to be relative to timing of 2nd vaccinat ion (a) 
 
 
 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
72 APPENDIX B: SCREENING TESTS  
Analyte  Unit  Acceptable Values for S creening  Labs:  
White Blood Cell count (WBC)  thou/mcL  3600 –11000 (2800 –11,000 for African -Americans)  
Absolute Neutrophil Count (ANC)  thou/mcL  1500 –8000  (1200 -8000 for African -Americans)  
Hemoglobin (Females)  g/dL  F: 11.5 –16.5  
Hemoglobin (Males)  g/dL  M: 13.0 –18.0  
Platelet count  per mm3 125,000 –450,000  
ALT IU/L  <50 
Creatinine (females)  mg/dL  < 1.6  
Creatinine (males)  mg/dL  < 1.6  
Bilirubin, total  mg/dL  < 1.4 (unless known Gilbert’s syndrome, then <2.0)  
Glucose - urinalysis  n/a trace or negative  
Protein - urinalysis  n/a ≤ 1+  
Occult blood - urinalysis  n/a trace or negative*  
Urine pregnancy test  n/a Negative  
Serum β -HCG  n/a Negative  
Hepatitis B surface antigen  n/a Negative  
Hepatitis C virus ELISA  n/a Negative ** 
HIV n/a Negative  
Stool Culture  n/a No Salmonella , Shigella , Campylobacter , Yersinia  or 
Vibrio  (The absence  of normal flora  or “no normal 
enteric flora present” is not acceptable)  
BioFire GI Panel (or equivalent 
molecular diagnostic test)  n/a  No Salmonella , Shigella /EIEC , Campylobacter , 
Yersinia , Vibrio , or Norovirus GI/GII.  
n/a, not applicable  
*presence is acceptable for menstruating women  
** instances where there is an “indeterminate” HCV antibody screening result may be 
acceptable if the participant can document a negative Hepatitis C virus viral load (e.g., 
undetected viral load or no measur able virus in a HCV RNA quantitative test)  
12-lead Electrocardiogram  Must not have any of the following, in order to be acceptable:  
• Pathologic Q wave abnormalities  
• Significant prolonged QT  
• Significant ST -T wave changes  
• Left ventricular hypertrophy  
• Right bundle branch block  
• Left bundle branch block  
• Advanced A -V heart block  
• Non -sinus rhythm, excluding isolated premature atrial 
contractions  
 
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
73 APPENDIX C: CLINICAL SAFETY LAB TOXICITY  
Test  Mild  
Grade 1  Moderate  
Grade 2  Severe  
Grade 3  Potentially Life 
Threatening  
Grade 4  
WBC, increase  1.1 – 1.5 xULN  1.6 – 2.0 xULN  2.1 – 2.5 xULN  ≥ 2.6 xULN  
WBC, decrease*  1.1 – 1.5 xLLN  1.6 – 2.0 xLLN  2.1 – 2.5 xLLN  ≥ 2.6 xLLN  
ANC decrease  1.1 – 1.5 xLLN  1.6 – 2.0 xLLN  2.1 – 2.5 xLLN  ≥ 2.6 xLLN  
Hemoglobin decrease  1.1 – 1.5 xLLN  1.6 – 2.0 xLLN  2.1 – 3.0 xLLN  >3 xLLN  
Platelet count  1.3 – 1.5 xLLN  1.6 – 2.0 xLLN  2.1 – 3.0 xLLN  >3 xLLN  
Sodium, low 132 -134 130 - 131 125 - 129 < 125  
Sodium, high  146 – 148 149 - 150 151 - 152 > 152  
Potassium, high  5.6 – 5.8 5.9 – 6.1 6.2 – 6.5 > 6.5  
Potassium, low  3.3 – 3.4 3.1 – 3.2 2.9 – 3.0 < 2.9 
Creatinine*  1.1 – 1.5 xULN  1.6 – 2.0 xULN  2.1 – 3.0 xULN  > 3.0 xULN  
AST (SGOT)  1.6 - 2.5 xULN  2.6 – 4.0 xULN  4.1 – 10.0 xULN  >10 xULN  
ALT (SGPT)  1.6 - 2.5 xULN  2.6 – 4.0 xULN  4.1 – 10.0 xULN  >10 xULN  
Alkaline Phosphatase  1.6 - 2.0 xULN  2.1 – 3.0 xULN  3.1 – 10.0 xULN  >10 xULN  
Total Bilirubin  1.2 - 1.5 xULN  1.6 – 2.0 xULN  2.1 - 4.0 xULN  >4 xULN  
ULN = upper limit of normal range  
LLN = lower limit of normal range  
*if the baseline is outside of the reference range (e.g., African -American acceptable value), then relative 
changes to the baseline value will be evaluated for toxicity  
 
 
  
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
74 APPENDIX D: ENDPOINT DEFINITIONS FOR SHIGELLOSIS  
Definition of Loose Stool by the Grading of Stool Consistency  
normal stool  loose  or diarrheal stool  
Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Well formed;  
does not take the 
shape of the container  Soft;  
does not easily take 
the shape of the 
container  Thick liquid stool; 
easily takes the shape 
of the container  Opaque watery 
diarrheal stool  Clear watery or “rice 
water” diarrheal stool  
 
Primary Endpoint s, Definition s for Moderate -Severe Shigellosis  Illness  
(according to the BMGF CHIM Working Group’s case definition for moderate -severe shigellosis ,  
any one of the below will satisfy as a primary endpoint ) 
Severe Diarrhea  ≥6 loose stools  in 24 hours OR >800 grams  of loose stools in 24 hours  
Moderate Diar rhea [4-5 loose stools in 24 hours OR 400-800 grams  of loose stools in 24 hours]  
AND   
[oral temperature ≥38.0˚C  (100.4°F)† OR ≥1 moderate constitutional/enteric symptom‡ OR ≥2 
episodes of vomiting in 24 hours]  
Dysentery  ≥2 loose stools with gross blood ( confirmed by fecal occult blood test ) in 24 hours  
AND      
[oral temperature ≥38.0˚C  (100.4°F)† OR ≥1 moderate constitutional/enteric symptom‡ OR ≥2 
episodes of vomiting in 24 hours]  
† Oral temp must be confirmed by two separate readings at least five min utes apart  
‡ Constitutional/enteric symptoms include: nausea, abdominal pain, abdominal cramping, myalgia, arthralgia, and malaise ;  
“moderate”  severity is defined as causing interference with routine activities; “severe” severity symptom is defined as 
causing the inability to perform routine daily activities . Anorexia, rigors/chills, tenesmus/fecal urgency, gas/flatulence, and 
headache  are not included symptoms  for the endpoint . 
 
Secondary  Endpoint s, Definitions for Shigellosis  Illness  
(according to pre viously used CVD case definitions for shigellosis)  
Diarrhea  ≥2 loose stools  totaling ≥200 grams in 24 hours OR a single loose stool of >300 grams  
Dysentery  ≥1 loose stool containing gross blood (confirmed by fecal occult blood test ) 
Fever  2 oral temperatures ≥37.8°C ( 100˚F), separated by at least 5 minutes apart  
Any illness  Satisfies any one of the three above criteria  
CVD historical 
definition of Severe 
Shigellosis  The criteria for both diarrhea and dysentery, according to the CVD defini tions  (above ), are met  
AND  
oral temperature of ≥38.9°C (102°F)† 
AND  
≥10 loose stools have been passed  
† Oral temp must be confirmed by two separate readings at least five minutes apart  
  
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
75 APPENDIX E: CRITERIA FOR THE EARLY INITIATION OF 
ANTIBIOTICS  
Events  which  trigger early antibiotic treatment  
(any one of the below criteria)  
The criteria for a primary endpoint of moderate -severe shigellosis (BMGF CHIM definitions) are met  
The criteria for the CVD historical definition of Severe Shigellosis  are met  
Oral temperature of ≥39°C (102.2°F)† 
Principal Investigator (PI or clinical designee) discretion, considering the overall safety and welfare of the 
participant  
† Oral temp must be confirmed by two separate readings at least five min utes apart  
 
  
Protocol Shigella CVD 30000  Version 14.0 
 04 October  2023 
 ________________________________ ________________________________ ____________________________   
 
 ________________________________ ________________________________ ____________________________   
76 APPENDIX F: SAMPLE FORM FOR THE COLLECTION OF 
SUBJECTIVE SYMPTOMS WHICH CONTRIBUTE TO THE 
SHIGELLA DISEASE SEVERITY SCORE  
 
